Effect of Antecedent Exercise on the Glycaemia-Increasing ...€¦ · To address this issue, eight...
Transcript of Effect of Antecedent Exercise on the Glycaemia-Increasing ...€¦ · To address this issue, eight...
Effect of Antecedent Exercise on the
Glycaemia-Increasing Response of a Short
Sprint: Implications for Blood Glucose
Management for Individuals with Type 1
Diabetes Mellitus
Tara Dawn Justice, BSc, BPHE
This thesis is presented in partial fulfilment for the degree of
Master of Science of The University of Western Australia
School of Sport Science, Exercise and Health
Faculty of Life and Physical Sciences
December 2011
ii
“Good, better, best. Never let it rest. Until your good is better
and your better is best” ~ Tim Duncan
iii
Executive Summary
Individuals with type 1 diabetes mellitus (T1DM) manage their blood glucose levels by
maintaining a careful balance between carbohydrate intake and exogenous insulin
administration. Although regular exercise affords numerous benefits to individuals with
T1DM, it can further complicate this balance, making management of blood glucose
levels more difficult. For example, moderate-intensity activity causes a rapid decline in
blood glucose levels both during exercise and early recovery, discouraging many
individuals with T1DM from participating in exercise due to the increased risk of
hypoglycaemia, a potentially life threatening condition. However, it is important to note
that not all types of exercise cause a decline in blood glucose levels. For instance, it has
recently been found that performance of short maximal sprints can attenuate the fall in
blood glucose levels both during (Guelfi et al., 2005) and after moderate-intensity
exercise (Bussau et al., 2006; Bussau et al., 2007; Guelfi et al., 2005) in individuals with
T1DM. However, before short maximal sprints can be safely added to exercise
guidelines for individuals with T1DM, factors that may reduce the glycaemia-increasing
benefit of a sprint need to be considered. In particular, the effect of an antecedent bout
of moderate-intensity exercise on the glycaemia-increasing response to a 30-second
maximal sprint performed several hours later needs to be investigated given that
previous research has shown a blunted counterregulatory hormone response to a second
bout of moderate-intensity exercise after an identical bout of exercise performed several
hours prior (Galassetti et al., 2001b).
To address this issue, eight healthy, physically active men without type 1 diabetes were
recruited. All individuals participated in three sessions, each separated by at least one
week. The first visit was a familiarization session in which baseline characteristics and
peak oxygen consumption ( O2peak) were determined. The second and third sessions
were administered following a randomized counterbalanced design, with participants
either cycling at 65% O2peak for 60 minutes (EX) or resting for an equivalent period
(CON). Following this, participants rested for 3 hours and 15 minutes prior to
performing a 30-second maximal sprint on a cycle ergometer. During the first hour of
recovery from the sprint, blood samples were taken and analyzed for blood glucose,
glucose kinetics, insulin, and the counterregulatory hormones: glucagon, epinephrine,
norepinephrine, cortisol, and growth hormone.
iv
In response to the 30-second maximal sprint, blood glucose levels increased
significantly and similarly above baseline following both trials, reaching a peak at 10
minutes of recovery. After this point, blood glucose levels began to steadily decline
towards baseline, with a more rapid decline following EX. Consequently, blood glucose
levels were significantly lower at 45 minutes of recovery (p = 0.024) following EX
compared to CON, and also tended to be lower in EX at 30 (p = 0.067) and 60
(p = 0.072) minutes of recovery. The increase in blood glucose levels in response to the
maximal sprint effort may be explained by a greater increment in glucose rate of
appearance (Ra) compared with glucose rate of disappearance (Rd) in early recovery (p
< 0.05), but may also be attributed to some extent to a large fluid shift out of the plasma.
However, the more rapid decline in blood glucose after the initial increase in EX cannot
be explained by a shift in plasma volume since the magnitude of plasma volume shift
was similar in both trials. Rather, this was associated with a higher Rd than Ra early
after the peak in blood glucose during recovery following EX compared with CON.
This is likely explained, at least in part, by the blunted growth hormone response and
increased insulin sensitivity in EX. Plasma insulin levels peaked similarly in both trials
at 30 minutes of recovery following the sprint, but were significantly lower in EX at 45
(p = 0.042) minutes of recovery. In addition, 60 minutes of antecedent exercise was
associated with significantly lower levels of growth hormone at 15 (p = 0.048), 30
(p = 0.025), and 45 (p = 0.028) minutes of recovery. There was no difference in cortisol
or norepinephrine between trials, while there was a small significant difference in
epinephrine at 15 minutes of recovery between trials, with slightly higher levels
following EX (p = 0.036). Glucagon increased at 60 minutes of recovery from EX,
likely in response to the rapid decline in blood glucose levels in this trial.
In summary, performance of antecedent exercise several hours prior to a 30-second
sprint does not affect the magnitude of the initial blood glucose increase, but does
accelerate the decline of blood glucose levels back to baseline. This raises the question
of whether antecedent exercise would have a similar effect in individuals with T1DM. If
so, individuals with T1DM should be cautious when performing a sprint after a bout of
antecedent exercise, as it may not be as effective as a sprint alone. Therefore, further
investigation of this phenomenon in individuals with T1DM is warranted before
complete guidelines can be given.
v
DECLARATION FOR THESES CONTAINING PUBLISHED WORK AND/OR WORK PREPARED FOR PUBLICATION
The examination of the thesis is an examination of the work of the student. The work must have been substantially conducted by the student during enrolment in the degree.
Where the thesis includes work to which others have contributed, the thesis must include a statement that makes the student’s contribution clear to the examiners. This may be in the form of a description of the precise contribution of the student to the work presented for examination and/or a statement of the percentage of the work that was done by the student.
In addition, in the case of co-authored publications included in the thesis, each author must give their signed permission for the work to be included. If signatures from all authors cannot be obtained, the statement detailing the student’s contribution to the work must be signed by the coordinating supervisor.
Please sign one of the statements below.
1. This thesis does not contain work that I have published, nor work under review for publication.
Student Signature…………………………………………………………………………………..
2. This thesis contains only sole-authored work, some of which has been published and/or prepared for publication under sole authorship. The bibliographical details of the work and where it appears in the thesis are outlined below.
Student Signature…………………………………………………………………………………...............
3. This thesis contains published work and/or work prepared for publication, some of which has been co-authored. The bibliographical details of the work and where it appears in the thesis are outlined below. The student must attach to this declaration a statement for each publication that clarifies the contribution of the student to the work. This may be in the form of a description of the precise contributions to the student to the published work and/or a statement of percent contribution by the student. This statement must be signed by all authors. If signatures from all the authors cannot be obtained, the statement detailing the student’s contribution to the published work must be signed by the coordinating supervisor.
Chapter 2 – “Effect of Antecedent Moderate-Intensity Exercise on the Glycaemia-Increasing Effect of a 30-second Maximal Sprint” will be prepared for publication in the near future.
Student Signature………………………………………………………………………………….
Coordinating Supervisor Signature………………………………………………………………..
vi
Statement of Candidate Contribution
The work involved in designing and conducting the study described in this thesis has
been conducted primarily by Tara Justice (the candidate). The thesis outline and
experimental design of the study was developed and planned by the candidate, in
consultation with Dr Kym Guelfi, Dr Paul Fournier, Dr Raymond Davey, & Dr Tim
Jones (the candidates supervisors). All participant recruitment and management was
carried out entirely by the candidate, along with the actual organization, implementation
and performance of the experiments, with the assistance of nursing staff for the purpose
of cannulation and infusion procedures, as well as research associates for blood
analysis. In addition, the candidate was responsible for all data analysis and original
drafting of the thesis. Dr Kym Guelfi, Dr Paul Fournier, Dr Raymond Davey, and Dr
Tim Jones have provided feedback for further drafts and polishing of the thesis and
manuscript.
Student Signature………………………………………………………………………………….
Coordinating Supervisor Signature………………………………………………………………..
vii
Table of Contents
Executive Summary………………………………………………………………. iii
Declaration for Thesis Containing Published Work And/Or Work Prepared for Publication………………………………………………………………………… v
Statement of Candidate Contribution……………………………………………... vi
Table of Contents…………………………………………………………………. vii
List of Tables……………………………………………………………………… xi
List of Figures……………………………………………………………………... xii
List of Abbreviations……………………………………………………………… xiii
Acknowledgments………………………………………………………………… xv
Chapter One: Introduction and Review of the Literature
1.1 Introduction……….. …………………………………………………….. 2
1.2 Type 1 Diabetes Mellitus………………………………………………... 3
1.3 Management of Type 1 Diabetes Mellitus………………………………. 5
1.4 Hyperglycaemia in Type 1 Diabetes Mellitus…………………………… 7
1.5 Hypoglycaemia in Type 1 Diabetes Mellitus……………………………. 8
1.5.1 Prevention and Correction of Hypoglycaemia in
Non-Diabetic Individuals……………………………………. 9
1.5.1.a Glucagon…………………………………………... 10
viii
1.5.1.b Catecholamines……………………………………. 10
1.5.1.c Growth Hormone and Cortisol…………………….. 11
1.5.2 Prevention and Correction of Hypoglycaemia in Individuals
with Type 1 Diabetes………………………………………….. 13
1.5.2.a Influence of Gender on the Response to
Hypoglycaemia…………………………………….. 14
1.5.2.b Influence of Prior Exercise on the Response to
Hypoglycaemia…………………………………….. 15
1.6 Exercise and Type 1 Diabetes Mellitus…………………………………... 16
1.6.1 Current Exercise Guidelines for Individuals
with Type 1 Diabetes………………………………………….. 17
1.7 Regulation of Blood Glucose Levels during Moderate-Intensity
Exercise and Recovery…………………………………………………… 18
1.7.1 Regulation of Blood Glucose Levels during Moderate-
Intensity Exercise in Non-Diabetic Individuals……………….. 18
1.7.2 Regulation of Blood Glucose Levels during Moderate-
Intensity Exercise in Individuals with Type 1 Diabetes………. 20
1.8 Regulation of Blood Glucose Levels during High-Intensity Exercise
and Recovery…………………………………………………………….. 23
1.8.1 Regulation of Blood Glucose Levels during High-Intensity
Exercise in Non-Diabetic Individuals………………………… 24
1.8.2 Regulation of Blood Glucose Levels during High-Intensity
Exercise in Individuals with Type 1 Diabetes………………… 26
1.9 Clinical Implications of High-Intensity Exercise as a Tool to Reduce
the Risk of Hypoglycaemia………………………………………………. 27
ix
1.10 Factors that May Influence the Glycaemia-Increasing Effect of a
Sprint in Individuals with Type 1 Diabetes……………………………… 29
1.10.1 Antecedent Hypoglycaemia…………………………………... 29
1.10.2 Antecedent Exercise…………………………………………... 30
1.11 Summary…………………………………………………………………. 32
1.12 Aims……………………………………………………………………… 32
1.13 Research Hypotheses…………………………………………………….. 33
1.14 Significance of the Study………………………………………………… 33
1.15 References………………………………………………………………... 34
Chapter Two: Effect of Antecedent Moderate-Intensity Exercise on the
Glycaemia-Increasing Effect of a 30-second Maximal Sprint
2.1. Abstract…………………………………………………………………... 50
2.2. Introduction………………………………………………………………. 51
2.3. Research Design and Methods…………………………………………… 53
2.3.1. Participants……………………………………………………. 53
2.3.2. Experimental Design………………………………………….. 54
2.3.3. Familiarization Session……………………………………….. 55
2.3.4. Experimental Trials…………………………………………… 55
2.3.5. Measurement of Blood Metabolites and Hormones…………... 58
2.3.6. Measurement of [6,6-2H] glucose enrichment, and glucose
Ra and Rd calculations………………………………………… 59
x
2.3.7. Statistical Analyses…………………………………………… 60
2.4. Results……………………………………………………………………. 60
2.4.1. Characteristics of the 60-minute antecedent bout of exercise
and maximal sprint efforts…………………………………….. 60
2.4.2. Blood glucose response to a 30-second maximal sprint………. 62
2.4.3. Glucose rate of appearance and rate of disappearance
determined without corrections in plasma volume……………. 63
2.4.4. Glucose rate of appearance and rate of disappearance when
corrected for plasma volume changes………………………… 64
2.4.5. Plasma insulin response to a 30-second maximal sprint……… 65
2.4.6. Counterregulatory hormone response to a 30-second
maximal sprint………………………………………………… 65
2.4.7. Blood lactate, blood pH, and heart rate responses to a 30-second
maximal sprint………………………………………………… 73
2.5. Discussion………………………………………………………………... 75
2.6. References………………………………………………………………... 80
Appendices
Appendix A: Testing Information Sheets and Consent Forms……………………. 87
Appendix B: Human Ethics Approval Form………………………………………. 91
Appendix C: Meal Record Sheet…………………………………………………... 96
Appendix D: Data Collection Sheets………………………………………………. 100
xi
List of Tables
2.1 Characteristics of Study Participants…………………………………….. 54
2.2 Response of oxygen consumption, blood lactate, and heart rate
to 60 minutes of antecedent exercise or rest (control)…………………… 61
2.3 Comparison of mean and peak power output during a 30-second
maximal sprint following 60 minutes of antecedent exercise or rest
(control)………………………………………………………………….. 62
2.4 Percent change in plasma volume (%∆PV) in response to a
30-second maximal sprint………………………………………………... 68
xii
List of Figures
2.1 Blood glucose response to a 30-second maximal sprint performed
after 60 minutes of exercise (EX) or rest (CON)………………………… 63
2.2a Glucose Ra and Rd in response to a 30-second maximal sprint
performed after 60 minutes of rest (CON)……………………………….. 67
2.2b Glucose Ra and Rd in response to a 30-second maximal sprint
performed after 60 minutes of exercise (EX)……………………………. 67
2.3 Change in haematocrit in response to a 30-second maximal sprint
performed after 60 minutes of exercise (EX) or rest (CON)…………….. 68
2.4a Glucose Ra and Rd in response to a 30-second maximal sprint
performed after 60 minutes of rest (CON) when corrected for plasma
volume changes………………………………………………………….. 69
2.4b Glucose Ra and Rd in response to a 30-second maximal sprint
performed after 60 minutes of exercise (EX) when corrected for
plasma volume changes………………………………………………….. 69
2.5 Plasma insulin response to a 30-second maximal sprint performed
after 60 minutes of exercise (EX) or rest (CON)………………………… 70
2.6 Plasma glucagon response to a 30-second maximal sprint performed
after 60 minutes of exercise (EX) or rest (CON)………………………… 70
2.7a Plasma epinephrine response to a 30-second maximal sprint performed
after 60 minutes of exercise (EX) or rest (CON)………………………… 71
2.7b Plasma norepinephrine response to a 30-second maximal sprint
performed after 60 minutes of exercise (EX) or rest (CON)…………….. 71
2.8 Plasma growth hormone response to a 30-second maximal sprint
performed after 60 minutes of exercise (EX) or rest (CON)…………….. 72
2.9 Plasma cortisol response to a 30-second maximal sprint performed
after 60 minutes of exercise (EX) or rest (CON)………………………… 72
2.10 Blood lactate response to a 30-second maximal sprint performed after
60 minutes of exercise (EX) or rest (CON)………………………………. 74
2.11 Blood pH response to a 30-second maximal sprint performed after
60 minutes of exercise (EX) or rest (CON)……………………………… 74
xiii
Abbreviations
alpha ANS autonomic nervous system ATP adenosine triphosphate beta BMI body mass index (weight/height2) bpm beats per minute BW body weight
°C degrees celsius CGMS continuous glucose monitoring system cm centimeter CON control (rest) condition
DKA diabetic ketoacidosis EX exercise condition
g gram GCMS gas chromatography mass spectrometry GLUT 2 glucose transporter type 2 GLUT 4 glucose transporter type 4 h hour H+ hydrogen ion HbA1C glycated haemoglobin HR heart rate HRmax maximal heart rate kg kilogram L liter m meter
xiv
mM millimolar mg milligram min minute mIu/L milli-international units per liter ml milliliter
nmol/L nanomoles per liter Pi inorganic phosphate pg/mL picograms per milliliter pmol/L picomoles per liter
Ra rate of appearance of glucose
Rd rate of disappearance of glucose
rpm revolutions per minute SD standard deviation SEM standard error of the mean
T1DM type 1 diabetes mellitus µU/ml microunits per milliliter
O2 rate of oxygen consumption
O2peak peak rate of oxygen consumption W watt
xv
Acknowledgements
There is no doubt that this thesis would not exist without the support, guidance, and hard work of several people.
To Kym – I am speechless. I honestly don’t think I could have asked for a more outstanding supervisor! I’m eternally grateful to be the student of a supervisor with
never-ending guidance, support, and encouragement like yours. You’ve made this year nothing short of a great experience, and I don’t think I can thank you enough!
To Paul – Your endless enthusiasm and love for research is highly contagious and has
fueled me all year long. When I think I have all the answers, you ask the question that I can’t answer. Thanks for your guidance and support over the year!
To “Butler” Ray – The number of hours we have worked together does not do justice to
the effort and dedication you had to my project. Between editing, drawing award-winning kinetics diagrams, and catering to the every need of my participants, I’m not too sure how you had time for your own work. Thank you for absolutely everything!!
To Tim – Your expertise and feedback regarding the experimental design
and final thesis has been greatly appreciated. Thanks so much!
To my Participants – You were the backbone of this thesis! Thank you for your time, sweat, oxygen, veins, blood, and feel-good-state. I appreciate your flexibility and dedication to my study. You kept me entertained and on my toes at the same time!
To Niru, Adam, & Heather at PMH – This study could not have happened without all of you! Your guidance, expertise, and humor have been invaluable throughout the research process. You’ve challenged me to improve my critical thinking and
scrabble skills. Every day in the lab had some good to it!
To Ang, Katherine, Dan, Elisa, Annie, and James – Thanks so much for the Redbull offers, technical support, coffee dates, pep talks, opportunities to procrastinate,
and advice. You’ve been an amazing support network and I can’t imagine a graduate program without people like you. I’ll miss you all!
To my housemates – Thanks for your endless support and entertainment when I
don’t want to think about school anymore. Remember, haters gonna hate!
To Chloe & my Camp Huronda family – Thank you for continuing to inspire me and giving me a reason to find answers. This thesis is dedicated to all of you!
To my family – Although you may be thousands of miles away, you never fail to support me in my pursuits. Although none of you understand my research at all,
your ability to smile and nod is always appreciated!
Chapter One
Introduction and Review of the Literature
2
1.1 Introduction
Individuals with type 1 diabetes mellitus aim to maintain blood glucose levels within
the normal physiological range of 4 to 8 mM. To achieve this goal, these individuals
must carefully balance their diet, physical activity, and exogenous insulin
administration. Regular blood glucose monitoring provides feedback to these
individuals and assists with decision-making regarding carbohydrate intake and insulin
administration. However, a balance is hard to achieve and blood glucose levels can
often deviate from the desired target range. A high blood glucose level
(hyperglycaemia) is a common occurrence for individuals with type 1 diabetes.
Unfortunately, chronic hyperglycaemia increases the risk of developing long-term
complications such as blindness, cardiovascular disease, and kidney failure. On the
other hand, a decline in blood glucose, often caused by the administration of too much
insulin, can lead to the onset of hypoglycaemia, a potentially life-threatening condition.
Another factor that increases the risk of hypoglycaemia is moderate-intensity exercise.
Regular exercise is a key component of any treatment plan for an individual with type 1
diabetes, but unfortunately moderate-intensity exercise causes a steady decline in blood
glucose levels thereby increasing the risk of hypoglycaemia during both exercise and
early recovery. However, it is often overlooked that different types of exercise have
different impacts on blood glucose levels. For instance, it has been shown that high-
intensity exercise causes blood glucose levels to increase, raising the possibility that this
type of exercise may be useful for the prevention of hypoglycaemia. As evidence for
this, the performance of a short 10-second maximal sprint before or after moderate-
intensity exercise has been shown to have a stabilizing effect on blood glucose levels
during early recovery, thereby reducing the risk of hypoglycaemia at this time.
However, before a short maximal sprint can be recommended as a tool for the
prevention of exercise-mediated hypoglycaemia, several factors that may alter the
glycaemia-increasing effect of a sprint, such as antecedent exercise, must be
investigated. Consequently, the primary goal of this thesis was to examine the effect of
antecedent moderate-intensity exercise on the blood glucose response to a short
maximal sprint performed later in the day. This issue was examined in non-diabetic
individuals to investigate how this factor influences the glycaemia-increasing effect of
sprinting under non-pathological conditions. The information obtained will form the
3
basis for future studies on individuals with type 1 diabetes and should provide valuable
information for management of blood glucose levels during exercise.
1.2 Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) represents 10-15% of all cases of diabetes in Australia
(Australian Diabetes Council, 2010). It currently affects 122,300 Australians, with 6
new cases diagnosed each day (Juvenile Diabetes Research Foundation, 2010a). T1DM
is most commonly diagnosed in children 15 years or younger and is the second most
common chronic disease in school-aged children, preceded only by asthma
(Strawhacker, 2001). However, diagnosis at an older age is still a possibility with
approximately 50% of patients diagnosed older than 20 years of age (Juvenile Diabetes
Research Foundation, 2006; Khardori, 2011).
T1DM is an autoimmune disease with onset occurring following destruction of the beta
cells of the pancreas, which are responsible for producing insulin. It is currently not
fully understood what triggers this autoimmune reaction, but it has been suggested that
both genetics and the environment may play a role (Juvenile Diabetes Research
Foundation, 2010a). Insulin is a key glucoregulatory hormone, which, in conjunction
with glucagon, helps to regulate blood glucose and circulating fatty acid levels.
Insulin’s primary role is to lower blood glucose levels by stimulating uptake of glucose
by insulin-sensitive cells and suppressing hepatic glucose production (Strawhacker,
2001). With respect to glucose uptake, insulin stimulates translocation of the glucose
transporter GLUT 4 from the intracellular storage site to the plasma membrane where it
readily transports glucose out of the bloodstream and into the cells, especially those of
skeletal muscle (Tuch et al., 2000). Insulin further decreases blood glucose by inhibiting
glycogenolysis and gluconeogenesis in the liver (Cherrington et al., 1998).
In individuals without diabetes, the level of circulating insulin is tightly regulated.
Insulin secretion by the pancreas is regulated primarily, but not exclusively, by the
blood glucose level itself (Henquin, 2000). As the blood glucose level rises, glucose
enters the beta cells of the pancreas via GLUT 2 transporters and is subsequently broken
down to produce adenosine triphosphate (ATP). The build-up of ATP within the beta
cells stimulates the secretion of insulin, which works through a negative feedback loop
4
to decrease the blood glucose level (Tuch et al., 2000). In this manner, insulin and blood
glucose work together to maintain euglycaemia in the bloodstream. For example, as
blood glucose levels rise, insulin secretion increases in an attempt to bring blood
glucose levels back to the euglycemic range, whereas low blood glucose levels inhibit
insulin secretion to conserve the limited supply of blood glucose.
In contrast, individuals with T1DM lack the ability to produce insulin. Insulin
deficiency in the body results in increased hepatic glucose production and a lack of
peripheral glucose uptake, causing glucose to accumulate in the bloodstream. A chronic
state of hyperglycaemia ensues, further exacerbated by an excessive increase in some
counterregulatory hormones (Goldstein et al., 1995). These counterregulatory hormones
include glucagon, epinephrine, norepinephrine, cortisol, and growth hormone. These
hormones normally function to oppose the action of insulin and some stimulate a rise in
blood glucose levels by activating hepatic glycogenolysis, inhibiting glucose uptake by
the tissues, and promoting the conversion of gluconeogenic precursors (i.e. lactate,
alanine, and glycerol) into glucose (Goldstein et al., 1995). However, the lack of insulin
production in T1DM means the actions of the counterregulatory hormones are
unopposed, with some such as glucagon reaching extremely high levels and causing
blood glucose levels to rise as a result. High levels of glucose in the blood cause glucose
to spill into the urine, causing increased urine output, which results in dehydration and
electrolyte loss (Lumb & Gallen, 2009). Consequently, hyperglycaemia presents with
symptoms of excessive thirst (polydipsia), excessive urination, (polyuria), and excessive
hunger (polyphagia), along with weight loss and blurred vision.
The absence of circulating insulin combined with excessively high levels of glucagon
results in a marked increase in plasma fatty acid levels. These factors in turn stimulate
hepatic ketogenesis, which causes ketone bodies (i.e. acetoacetate, acetone, and 3-ß-
hydroxybuturate) to accumulate in the blood, causing metabolic acidosis due to their
weak acidic properties. The combination of high blood glucose levels, high ketone
levels, and metabolic acidosis is often referred to as diabetic ketoacidosis (DKA), and is
often present at the time of diagnosis of T1DM (American Diabetes Association, 2011).
Left untreated, DKA can lead to a diabetic coma or even death (Kitabchi et al., 2001).
Another acute complication of high blood glucose is increased risk of septicemia
(Kitabchi et al., 2001). Hyperglycaemic conditions are conducive to the growth of
bacteria and can aggravate what might have been a minor infection otherwise. For these
reasons, individuals with T1DM die often within 1 to 2 years if left untreated.
5
1.3 Management of Type 1 Diabetes Mellitus
There is currently no cure for T1DM. However, the discovery of insulin in 1921 has
greatly enhanced the quality of life and life expectancy of those individuals living with
the disease. Currently, treatment of the condition involves maintaining blood glucose
within the normal physiological range (4 to 8 mM) with the administration of
exogenous insulin, typically via multiple daily injections with a syringe or insulin pen.
Initially, several varieties of animal-sourced insulin, such as bovine (cow) and porcine
(pig), were used for treatment. Today, most varieties of administered insulin are
biosynthetic recombinant ‘human’ insulin or its analogs.
There are currently a number of different insulin analogs with various pharmacokinetic
properties (i.e. absorption rate, duration, and time of peak action) available to
individuals with T1DM to optimize their blood glucose control. Most individuals
combine a rapid-acting insulin (e.g. insulin Aspart or Lispro), typically absorbed within
5 to 15 minutes of administration and peaking 30 to 90 minutes later, with a long-acting
insulin (e.g. insulin Glargine or Detemir) that has a delayed absorption and peaks
between 4 to 12 hours after administration (Shalitin & Phillip, 2008). The rapid-acting
insulin is used to combat the large and rapid postprandial rises in blood glucose,
attempting to mimic the normal insulin secretion following a meal. For this reason, it is
typically administered just prior to eating. On the other hand, long-acting insulins are
designed to mimic the basal secretion of insulin over the course of the day and
throughout the night. This form of insulin is responsible for combating small
fluctuations in blood glucose as a result of stress and daily activities, and is
administered once or twice daily at a predetermined time (Shalitin & Phillip, 2008).
Two therapeutic approaches have been used in the treatment of diabetes, with intensive
therapy more widely used than conventional therapy today (Strawhacker, 2001).
Intensive therapy incorporates three or more daily insulin injections, comprising one or
two daily injections of long-acting insulin and multiple daily injections of rapid-acting
insulin in conjunction with meals to mimic the natural secretion of insulin (The
Diabetes Control and Complications Trial, 1993). Frequent blood glucose monitoring
and strict glycaemic targets accompany intensive therapy. On the other hand,
conventional therapy involves twice-daily insulin injections, which contain a mixture of
short and long acting insulins, and a wider range of acceptable blood glucose levels
(Strawhacker, 2001). The general adoption of intensive therapy is the result of The
6
Diabetes Control and Complications Trial, which found marked reductions in several
diabetic complications following intensive therapy aimed at normalizing blood glucose
levels in T1DM (The Diabetes Control and Complications Trial Group, 1993).
Recently, however, the development of the subcutaneous insulin pump has removed the
need for injections for those on intensive regimens. The insulin pump delivers rapid-
acting insulin at a basal rate throughout the day through a catheter inserted
subcutaneously into the abdomen, and has the ability to deliver a bolus of insulin when
carbohydrates are consumed (Strawhacker, 2001). These devices attempt to match the
activity of a healthy pancreas and are a big step towards a closed-loop regulation
system, the ultimate goal of diabetic technological advances.
Although exogenous administration of insulin greatly helps to maintain blood glucose
levels within a reasonable range, it is important to note that an excess of insulin can
have potentially fatal consequences. For this reason, individuals with T1DM must
undergo regular blood glucose monitoring prior to making any decisions about insulin
administration, food intake, or exercise. The advent of portable blood glucose meters
makes this a relatively simple process, with most meters requiring only a single drop of
capillary blood from the fingertip and giving results within seconds (American Diabetes
Association, 1997). It is generally recommended that individuals following an intensive
therapeutic regimen monitor their blood glucose level 3 to 4 times per day
(Strawhacker, 2001). Strategically placing these checks before meals and sleep allows
an individual to make informed decisions about carbohydrate intake and insulin
administration. However, a shortcoming of blood glucose monitoring is that it only
provides the immediate blood glucose level and does not show any possible fluctuations
between tests. The recent development of continuous glucose monitoring systems
(CGMS) overcomes this shortcoming, providing nearly continuous estimates of blood
glucose. The small, lightweight sensor measures subcutaneous tissue interstitial glucose
levels every 5 minutes, and transmits this information to a monitor worn on clothing or
a belt (Kaufman et al., 2001). The data can then be uploaded onto a computer where
glucose values and trends can be seen, providing a guide for individuals with T1DM.
Unfortunately, the current sensors only have a recommended lifespan of a few days,
making CGMS a very expensive system and, consequently, not accessible to everyone
with T1DM.
Patients’ success at maintaining blood glucose levels within the physiological range is
assessed indirectly by the measurement of their glycosylated haemoglobin, otherwise
7
known as HbA1C, a commonly used test and currently the gold standard measurement of
long-term glycaemic control. As glucose circulates in the blood, some glucose
glycosylates haemoglobin, which remains this way until the death of the red blood cell.
Since the red blood cell has an approximate lifespan of 120 days, a measurement of
HbA1C provides an indication of the average blood glucose level over the preceding 120
days (American Diabetes Association Position Statement, 2011; Sacks et al., 2002;
Shemin & Rittenberg, 1946). For example, a high HbA1C reading (>7.5%) indicates that
blood glucose levels were often above the desired target range during the 120 days. In
this manner, HbA1C tests can highlight poor glycaemic control even if regular blood
glucose monitoring suggests that the individual is in good control.
1.4 Hyperglycaemia in Type 1 Diabetes Mellitus
Consistently achieving the perfect balance between administered insulin and
carbohydrate intake is very difficult, and blood glucose fluctuations outside of the
normal physiological range (4 to 8 mM) often occur. Hyperglycaemia, defined as blood
glucose in excess of 8 mM, is often the result of inadequate insulin intake for a specified
amount of carbohydrate. The occurrence of chronic hyperglycaemia over a number of
years carries an increased risk of long-term health complications (The Diabetes Control
and Complications Trial Group, 1993). These include vision problems, nerve damage,
kidney disease, and cardiovascular problems (Juvenile Diabetes Research Foundation,
2010b).
A common long-term complication of T1DM is proliferative retinopathy, which
accounts for most cases of lost vision in the Western Hemisphere (Chiarelli et al.,
2005). This condition results from impaired regulation of blood flow in the microvessels
of the eye due to chronic hyperglycaemia, eventually causing small reductions in vision
which may progress to complete blindness (Chiarelli et al., 2005). Another complication
associated with chronic hyperglycaemia is the development of kidney disease, otherwise
known as nephropathy, which holds the highest mortality rate of all complications
(Jabbour, 2007). High levels of blood glucose stress the kidneys over time and cause
irreversible damage, ultimately resulting in end-stage renal disease (The Diabetes
Control and Complications Trial Research Group, 1995). Furthermore, T1DM
8
accelerates the progression of macrovascular disease. Mortality and morbidity from
various forms of cardiovascular disease (myocardial infarction, stroke, and
hypertension) is markedly increased in individuals with T1DM when compared to non-
diabetic individuals (Soedamah-Muthu et al., 2006). This is the result of high blood
glucose levels accelerating the progression of early atherosclerotic lesions (Krolewski et
al., 1987). Finally, chronic hyperglycaemia causes the development of both peripheral
and autonomic neuropathy. High levels of blood glucose cause atrophy of nerve fibers,
loss of myelinated and unmyelinated nerve fibers, and blunting of nerve fiber
regeneration (Greene et al., 1992). This results in abnormal nerve function in a number
of body systems. Peripheral neuropathy predisposes individuals with diabetes to skin
ulceration, gangrene, and potential amputation (Peirce, 1999). It is often sensed as a
feeling of coldness, tingling, or numbness in the extremities. On the other hand,
autonomic neuropathy can cause postural hypotension, vomiting, bladder paresis, and
sudden death (Chiarelli et al., 2005). The risk of developing any of these complications
can be greatly reduced by the use of intensive therapy to keep blood glucose levels
within the normal physiological range of 4 to 8 mM (The Diabetes Control and
Complications Trial, 1993).
1.5 Hypoglycaemia in Type 1 Diabetes Mellitus
Although the use of intensive therapy greatly reduces the risk of the longer-term
complications associated with hyperglycaemia, it is not without its disadvantages.
Intensive therapy is associated with an approximate threefold increase in the incidence
of severe hypoglycaemia, limiting the widespread implementation of this treatment
paradigm (The Diabetes Control & Complications Trial, 1993). Hypoglycaemia is a
condition characterized by blood glucose levels below 3.0 – 3.8 mM and is experienced
often by individuals with T1DM (Chiarelli et al., 1999). The average person with
T1DM experiences numerous asymptomatic episodes, thousands of symptomatic
episodes, and several severe (i.e. temporarily disabling) episodes of hypoglycaemia in
their lifetime (Chiarelli et al., 1999). Hypoglycaemia occurs since individuals with
T1DM cannot control their circulating level of insulin; rather, it is determined solely by
the amount, timing, and pharmacokinetics of the administered insulin. For this reason, a
9
relative insulin excess, as a result of insulin doses that are excessive or ill timed, can
cause hypoglycaemia (Rattarasarn et al., 1994).
The onset of hypoglycaemia is accompanied by a number of symptoms that can be
generally classified into one of two categories. Neurogenic symptoms, which include
anxiety, palpitations, hunger, sweating, irritability, tachycardia, and tremors, are caused
by hypoglycaemia-induced activation of the ANS (Bolli, 2003; Cryer et al., 2003). On
the other hand, neuroglycopenic symptoms are a result of glucose deprivation in the
brain. The brain is heavily reliant upon the delivery of glucose as it stores little in the
form of glycogen (Bolli, 2003; Cryer et al., 2003). Neuroglycopenic symptoms include
dizziness, tingling, blurred vision, difficulty thinking, and loss of coordination, and can
extend to convulsions, unconsciousness, brain damage, and even death when
hypoglycaemia is severe (Bolli, 2003). Detection of hypoglycaemia is largely due to
perception of these symptoms and recognition that they are indicative of hypoglycaemia
to allow for appropriate action to be taken.
1.5.1 Prevention and Correction of Hypoglycaemia in Non-Diabetic Individuals
In non-diabetic individuals, insulin and the counterregulatory hormones act
antagonistically to prevent hypoglycaemia. A negative feedback system involving
glucose and the glucoregulatory hormones allows for tight control and minimal
fluctuation of the blood glucose level from the normal physiological range. When blood
glucose levels decline to 4.5 mM, decreasing the circulating level of insulin is the first
corrective measure taken (Cryer et al., 2003). Insulin secretion by the pancreas virtually
ceases during hypoglycaemia in non-diabetic individuals, helping to restore
euglycaemia by stimulating increased hepatic glucose production and inhibiting glucose
uptake by the insulin-sensitive tissues (Cryer et al., 2003). If blood glucose levels
continue to decline to 3.6 to 3.9 mM, the counterregulatory hormones begin to play a
vital role. Glucagon and the catecholamines are the most important counterregulatory
hormones, followed by growth hormone and cortisol, which have been shown to have
lesser but longer-lasting effects (Rizza et al., 1979; Rosen et al., 1984). The
counterregulatory hormones help restore euglycaemia by stimulating endogenous
glucose production, increasing lipolysis, and limiting glucose uptake by tissues other
than the brain (Cryer et al., 2003).
10
1.5.1.a Glucagon
Glucagon is the primary counterregulatory hormone in non-diabetic individuals.
Glucagon is a single chain 29-amino acid polypeptide hormone that is secreted by the
alpha cells of the Islets of Langerhans of the pancreas (Jiang & Zhang, 2003). It is
secreted in a pulsatile fashion in response to low circulating levels of blood glucose as it
plays a role in returning blood glucose to the normal physiological range (Jiang &
Zhang, 2003; Opara et al., 1988). Glucagon acts by decreasing glycogen synthesis and
increasing the rate of hepatic glucose production via activation of glycogenolysis and
gluconeogenesis (Cryer et al., 2003; Jiang & Zhang, 2003). The primary role of
glucagon in glucose counterregulation has been demonstrated in studies where glucagon
secretion is impaired, resulting in reduced hepatic glucose production (Bolli et al., 1984;
Jiang & Zhang, 2003; Rizza et al., 1979). The importance of glucagon is further
supported by its clinical usage in treating insulin-induced hypoglycaemia in individuals
unable to self-treat with sugary drinks or snacks (Davis et al., 2000b; Draznin, 2000;
Haymond & Schreiner, 2001). An emergency injection of glucagon subcutaneously or
intramuscularly during an episode of severe hypoglycaemia quickly increases blood
glucose levels, primarily through the conversion of liver glycogen stores to glucose
(Fonjallaz & Loumaye, 2000; Unger & Orci, 1994).
Glucagon’s importance mainly lies in its acute effect on hypoglycaemia. Fortunately,
only a small amount of glucagon is needed to significantly raise blood glucose levels
(Myers et al., 1991; Sandoval et al., 2004; Strawhacker, 2001). The glucose-rising effect
of glucagon occurs within minutes and dissipates rapidly, highlighting the need for
pulsatile secretion (Dobbins et al., 1998). However, the main factor of interest for the
maintenance of blood glucose levels is the ratio of insulin to glucagon. A high ratio of
insulin to glucagon will cause blood glucose levels to decline through stimulation of
glucose uptake by the tissues and inhibition of hepatic glucose production, and vice
versa when the ratio is low (Boyle et al., 1989).
1.5.1.b Catecholamines
The catecholamines, namely epinephrine and norepinephrine, are part of the
sympathetic nervous system and play a secondary role to glucagon in glucose
11
counterregulation. The catecholamines are released in response to stress and form part
of the body’s fight-or-flight response. The adrenal medulla is the main site of
production, secreting 80% epinephrine and 20% norepinephrine, with norepinephrine
also being secreted from the endings of sympathetic neurons (Klabunde, 2008).
Like glucagon, the catecholamines are secreted in response to low blood glucose levels
(Porcellati et al., 2003). They increase blood glucose levels by stimulating increased
hepatic glucose production via glycogenolysis and gluconeogenesis and decreasing
glucose uptake by the tissues (Cryer et al., 2003). A rise in plasma epinephrine has been
shown to initially increase hepatic glycogenolysis and later hepatic gluconeogenesis
when the hepatic glycogen stores begin to deplete (Goldstein et al., 1995). Furthermore,
epinephrine has been shown to decrease glucose clearance from the blood and thus
further stimulate a rise in blood glucose (Rizza et al., 1979).
However, the catecholamines are not essential for acute glucose counterregulation in
non-diabetic individuals. Their importance in glucose counterregulation emerges when
glucagon secretion is deficient. A number of studies have found increased
catecholamine levels when somatostatin and insulin have been infused to suppress
glucagon secretion. Under these conditions, catecholamine levels rise in an attempt to
compensate for the lack of glucagon and return blood glucose back to the normal
physiological range (Boyle et al., 1989; Cryer et al., 2003; Rizza et al., 1979; Rosen et
al., 1984). Although not essential, the catecholamines do still play a role when glucagon
is present. A substantial decrease in blood glucose elicits secretion of the
catecholamines, which work in conjunction with glucagon to prevent hypoglycaemia
and return blood glucose back to the normal physiological range (Rosen et al., 1984).
1.5.1.c Growth Hormone & Cortisol
Growth hormone and cortisol are counterregulatory hormones that make small
contributions to glucoregulation. Growth hormone is released from the anterior pituitary
gland while cortisol is released from the adrenal cortex, both being released in a
pulsatile pattern (Kanaley & Hartman, 2002). These hormones have a more progressive
and longer lasting-effect on blood glucose level than glucagon or epinephrine, with their
main benefit lying in their contribution to preventing prolonged hypoglycaemia (Boyle
& Cryer, 1991). Both hormones limit glucose uptake and support glucose production
12
over a longer time frame (hours) (Cryer et al., 2003). Conversely, these hormones are
unlikely to play a role in acute recovery from hypoglycaemia since recovery from
hypoglycaemia has been observed in the absence of these hormones (Boyle & Cryer,
1991; Rizza et al., 1979). Furthermore, when growth hormone and cortisol are the only
two hormones present, hypoglycaemia still progresses, again suggesting that they do not
have an important role (Boyle et al., 1989). Previous studies have shown that 3 to 4
hours of hypoglycaemia is required before growth hormone or cortisol has a significant
effect on blood glucose regulation (Rizza et al., 1979). This has been shown with the
combined infusion of somatostatin and growth hormone, which causes inhibition of
glucagon and insulin secretion and allows the effects of growth hormone and cortisol to
be isolated (Rizza et al., 1979). When growth hormone and cortisol do take effect, they
begin by acting on the liver to increase hepatic glucose production, with further delayed
effects on glucose uptake (De Feo et al., 1989a; De Feo et al., 1989b). For this reason, it
has been proposed that both hormones have a more pronounced effect on glucose
production than uptake (De Feo et al., 1989a; De Feo et al., 1989b). However, research
performed over the past decade has shown that a sudden increase in growth hormone
levels can acutely inhibit peripheral glucose utilization rate (Møller et al., 1990; Møller
et al., 1992).
Of note, although cortisol appears to play a role in long-term prevention of
hypoglycaemia, it may also play a role in increasing the risk of hypoglycaemia under
certain conditions. Cortisol is potentially responsible for the blunting of
counterregulatory responses to hypoglycaemia after an antecedent stress. Exercise and
hypoglycaemia, both stresses to the body, have been shown to increase cortisol levels,
which subsequently blunt autonomic hormone responses to any subsequent
hypoglycaemic episodes (Bao et al., 2009; Davis et al., 1996; Galassetti et al., 2001a;
Sandoval et al., 2004). When cortisol levels are suppressed during the initial stressor,
responses to the subsequent hypoglycemic episode are preserved (Davis et al., 1996).
However, it is important to note that not all studies support a role for cortisol in the
blunting of counterregulatory responses (Goldberg et al., 2006; Raju et al., 2003).
13
1.5.2 Prevention and Correction of Hypoglycaemia in Individuals with Type 1 Diabetes
In comparison to non-diabetic individuals, the defense against hypoglycaemia is not as
well coordinated in individuals with T1DM. Impairments in several of the basic
components of the counterregulatory response cause a 25-fold increased risk for severe
hypoglycaemia in this population compared to non-diabetic individuals (Gosmanov et
al., 2005). First and foremost, individuals with T1DM lose the ability to endogenously
decrease their circulating level of insulin, which is normally the first line of defense
against an episode of hypoglycaemia (Cryer et al., 2003). Their circulating level of
insulin is instead determined by the rate of passive absorption from the site of
administration and the pharmacokinetics of the administered insulin. As a result, a fall
in blood glucose cannot be attenuated by a decline in insulin secretion, and the level of
hypoglycaemia worsens.
Furthermore, the release of counterregulatory hormones has been shown to be
suboptimal in this population (Cryer et al., 2003; Ertl & Davis, 2004; Galassetti et al.,
2003). The second line of defense against hypoglycaemia, the increase in glucagon
secretion, is usually lost early in the course of the disease (Gosmanov et al., 2005). In
healthy individuals, it is the decrease in the beta cell secretion of insulin that causes an
increase in glucagon secretion by the alpha cells (Gosmanov et al., 2005). For this
reason, it is suggested that the lack of a change in the beta cell activity in individuals
with T1DM might explain the impaired glucagon response. As a result of the impaired
glucagon response to hypoglycaemia, the catecholamine response becomes essential in
individuals with T1DM (Bolli, 1990). However, this response may also be attenuated in
individuals with T1DM, causing the clinical syndrome of defective glucose
counterregulation (Amiel et al., 1988; Bolli et al., 1983; Bolli et al., 1984). In addition,
the glycemic threshold for a counterregulatory response is often shifted to a lower blood
glucose level in this population, making the risk of severe hypoglycaemia even greater
(Amiel et al., 1988). The shift in the glycemic threshold to a lower level is a result of
intensive therapy and antecedent episodes of hypoglycaemia, which are responsible for
making the body accustomed to lower blood glucose levels (Dagogo-Jack et al., 1993).
Fortunately, most individuals with T1DM are able to recognize the warning signs and
symptoms of hypoglycaemia and can treat themselves immediately by ingesting sugary
drinks or snacks. Hypoglycaemia is usually treated with fast-acting carbohydrates to
14
prevent any further decline in blood glucose levels, and occasionally with intramuscular
injection of glucagon if oral intake of carbohydrates is not possible (Davis et al., 2000b;
Draznin, 2000, Haymond & Schreiner, 2001). However, some intensively treated
patients lose the ability to detect the neurogenic symptoms of hypoglycaemia and suffer
from hypoglycaemia-associated autonomic failure (Bolli, 2003; Cryer et al., 2003;
Dagogo-Jack et al., 1993). Hypoglycaemia unawareness, one part of hypoglycaemia-
associated autonomic failure, can be the result of recurrent episodes of hypoglycaemia.
It increases the risk of experiencing severe hypoglycaemia as the individual cannot
detect and thus treat episodes of hypoglycaemia (Rattarsarn et al., 1994). Recurrent
episodes of hypoglycaemia also impair the autonomic counterregulatory responses,
specifically the catecholamine response, to subsequent episodes of hypoglycaemia
(Davis et al., 1997; Fanelli et al., 1993; Heller & Cryer, 1991). Of interest, several
studies have shown that 2 to 3 weeks of avoiding hypoglycaemia can reverse
hypoglycaemia-associated autonomic failure in most patients. This includes a return of
the epinephrine counterregulatory response, an improved ability to detect neurogenic
symptoms, and a normalization of the threshold at which symptoms occur (Cryer et al.,
2003; Fanelli et al., 1993). Unfortunately, the responses of glucagon and norepinephrine
remain attenuated.
1.5.2.a Influence of Gender on the Response to Hypoglycaemia
Gender has been determined to be a key factor in the response to hypoglycaemia.
Firstly, it has been suggested that women have a lower blood glucose threshold for
counterregulatory hormone release since blood glucose must drop even lower than in
men before a response is evoked (Davis et al., 1993; Davis et al., 2000d; Widom et al.,
1991). Furthermore, in response to a given level of hypoglycaemia with equivalent
insulinemia, women display a lesser counterregulatory response than men (Amiel et al.,
1993; Davis et al., 1993; Diamond et al., 1993). Compared to men, women also show
reduced epinephrine, norepinephrine, and growth hormone responses to equivalent
levels of hypoglycaemia (Davis et al., 2000a). Based on these responses, it might be
assumed that the incidence of hypoglycaemia would be higher in women with T1DM
compared to men with T1DM since this population is highly reliant on epinephrine
(Davis et al., 2000a). However, the incidence of severe hypoglycaemia is gender neutral
possibly in part from women having greater resistance to the blunting effects of
15
antecedent hypoglycaemia (Davis et al., 2000d). A study completed with several levels
of antecedent hypoglycaemia (3.9 mM, 3.3 mM, and 2.9 mM) showed that women only
had limited blunting of their counterregulatory responses after antecedent
hypoglycaemia of 2.9 mM, while men exhibited blunted responses after all levels of
antecedent hypoglycaemia (Davis et al., 2000d). In fact, antecedent hypoglycaemia of
2.9 mM in women and 3.9 mM in men produced equivalent counterregulatory failure
(Davis et al., 2000d). Thus, women’s resistance to the blunting of these responses by
antecedent hypoglycaemia may balance out their innate reduced autonomic responses to
hypoglycaemia and explain the similar incidence of hypoglycaemia in both genders.
1.5.2.b Influence of Prior Exercise on the Response to Hypoglycaemia
Antecedent exercise may also blunt the counterregulatory response to subsequent
episodes of hypoglycaemia (Galassetti et al., 2001a). In a study involving non-diabetic
individuals, epinephrine, norepinephrine, glucagon, and growth hormone responses to
next-day hypoglycaemia were blunted after two 90-minute bouts of antecedent
moderate-intensity exercise at 50% O2max separated by 180 minutes (Galassetti et al.,
2001a). These effects have also been observed using low- (30% O2max) and
moderate- (50% O2max) intensity exercise in individuals with T1DM (Sandoval et al.,
2004). After two 90-minute bouts of antecedent exercise at either intensity separated by
180 minutes, individuals with T1DM exhibited blunted autonomic, epinephrine, and
symptomatic responses to subsequent hypoglycaemia compared to a resting control
condition (Sandoval et al., 2004). However, no differences in the norepinephrine,
growth hormone, or cortisol responses to hypoglycaemia were noted. Of interest, the
epinephrine response to hypoglycaemia also appeared to be blunted to a greater extent
in individuals with T1DM compared to non-diabetic individuals, suggesting that
individuals with T1DM may experience slightly greater counterregulatory failure after
an antecedent stressor (Galassetti et al., 2001a; Sandoval et al., 2004). In spite of the
various reported amounts of blunting, it is clear that antecedent exercise does act as a
stressor and exerts some blunting effect on the counterregulatory hormone response to
subsequent hypoglycaemia.
16
1.6 Exercise and Type 1 Diabetes Mellitus
Although antecedent exercise may blunt the counterregulatory response to subsequent
hypoglycaemia, regular exercise remains a key component of any T1DM management
plan. The American Diabetes Association’s position statement on exercise states that,
“all patients with diabetes should have the opportunity to benefit from the many
valuable effects of exercise” (American Diabetes Association Position, 1999). Regular
exercise affords many health benefits, including lower risk of macrovascular disease,
obesity, hypertension, certain cancers, and all-cause mortality (Colberg & Swain, 2000).
Exercise has also been shown to have psychological benefits, including improved self-
esteem, reduced anxiety, and lower levels of depression (Morgan, 1985; Sonstroem &
Morgan, 1989). Furthermore, exercise confers many additional benefits that are specific
to individuals with T1DM such as improved insulin sensitivity and enhanced glucose
uptake, which can reduce the requirement for exogenous insulin and assist in the
management of blood glucose levels (White & Sherman, 1999).
For these reasons, many individuals with T1DM could greatly benefit from exercise;
however, they are often discouraged from engaging in a physically active lifestyle
because of the increased risk of hypoglycaemia (Choi & Chisholm, 1996). The risk of
hypoglycaemia is increased both during (Tsalikian et al., 2005; Tuominen et al., 1995)
and for up to 31 hours after moderate-intensity exercise (Macdonald, 1987; McMahon
et al., 2007). The increased risk of hypoglycaemia during exercise is the result of an
inability of individuals with T1DM to both decrease the circulating level of insulin and
mount an adequate counterregulatory hormone response. High circulating insulin levels,
when combined with exercise-mediated glucose uptake, causes accelerated uptake of
glucose into the peripheral tissues, resulting in a lowering of blood glucose levels
(Lumb & Gallen, 2009). Although the risk of exercise-induced hypoglycaemia is a
legitimate fear, the benefits of regular physical activity almost certainly outweigh the
risks in the majority of individuals with T1DM, including those with some
complications (Riddell & Perkins, 2006). This is because it is possible to effectively
manage blood glucose levels during exercise and recovery by adjusting exogenous
insulin administration and nutrition to minimize the risk of hypoglycaemia (Guelfi et
al., 2007a).
17
1.6.1 Current Exercise Guidelines for Individuals with Type 1 Diabetes
The American College of Sports Medicine recommends that individuals with T1DM
participate in aerobic exercise on a minimum of 3 to 5 days a week for 20 to 60 minutes
as well as resistance training that includes one set of 8 to 10 exercises using the major
muscle groups on 2 to 3 days per week (American College of Sports Medicine, 1998;
Hornsby & Albright, 2009). In an attempt to encourage participation, numerous
researchers and physicians have published specific exercise guidelines and
recommendations for individuals with T1DM to help minimize the risk of
hypoglycaemic episodes (Colberg, 2000a; Dawson, 2002; Draznin, 2000; Draznin,
2010; Lumb & Gallen, 2009; Riddell & Perkins, 2006). Many guidelines suggest a
decrease in the amount of insulin given prior to exercise and additional ingestion of
carbohydrates before, during, and after exercise. In a study performed by Rabasa-Lhoret
and colleagues (2001), a 50-75% reduction in the amount of rapid-acting insulin
administered with a meal 90 minutes prior to exercise at 25, 50, or 75% O2max
reduced the incidence of exercise-induced hypoglycaemia by 75%. However, utilization
of this strategy requires that the exercise be planned, which is often not the case. In this
respect, carbohydrate supplementation is a useful alternative. The American Diabetes
Association (2004) recommends ingestion of carbohydrates if blood glucose is below
5.5 mM prior to exercise, and the consumption of additional carbohydrates throughout
exercise as needed to prevent hypoglycaemia.
While such guidelines provide a useful starting point, specific recommendations for
avoiding hypoglycaemia during exercise are lacking. This is because a number of
factors can influence the glycaemic response to exercise, including the time elapsed
since the last meal, individual variability in the glycaemic response to exercise, and the
insulin regimen followed (Colberg, 2000b; Riddell & Perkins, 2006). Furthermore, not
all types of exercise increase the risk of hypoglycaemia. A limitation of the current
recommendations is that they often do not differentiate between moderate- and high-
intensity exercise, which have been shown to have contrasting effects on blood glucose
levels, and thus require different management strategies if hypoglycaemia is to be
avoided (Guelfi et al., 2007a; Riddell & Perkins, 2006). In general, most
recommendations suggest a trial and error approach to learn the glycaemic responses to
different types of exercise through frequent blood glucose monitoring in a variety of
activities (Colberg & Swain, 2000). The trial and error approach is worthwhile for these
18
individuals since it has been found that blood glucose responses to exercise have some
degree of reproducibility (Temple et al., 1995). However, there remains a considerable
need to individualize and add to these recommendations, specifically addressing
different intensities of activity. Since different intensities of exercise produce different
glycaemic responses, an understanding of the metabolic and hormonal responses to
different intensities of exercise is necessary to avoid exercise-induced hypoglycaemia
and to ensure usage of the correct blood glucose management strategies.
1.7 Regulation of Blood Glucose Levels during Moderate-Intensity Exercise and Recovery
Most published exercise guidelines for individuals with T1DM address moderate-
intensity exercise. Moderate-intensity exercise is defined as exercise at 40-59% of an
individual’s maximal oxygen consumption ( O2max) or 55-69% of maximal heart rate
(HRmax), and includes continuous aerobic activities such as jogging, swimming, and
cycling (American Diabetes Association Position Statement, 2004). It is principally this
intensity of activity that carries an increased risk of hypoglycaemia, both during
(Tuominen et al., 1995) and for up to 31 hours of recovery (Macdonald, 1987). This
increased risk of hypoglycaemia with moderate-intensity exercise is a result of a
mismatch between glucose production and glucose uptake, as well as a defective
counterregulatory hormone response (Macdonald, 1987; McMahon et al., 2007). For
this reason, individuals with T1DM should frequently monitor their blood glucose and
often need to make adjustments in insulin administration and carbohydrate intake
before, during, and after this type of exercise.
1.7.1 Regulation of Blood Glucose Levels during Moderate-Intensity Exercise in Non-Diabetic Individuals
In order to understand how moderate-intensity exercise increases the risk of
hypoglycaemia in individuals with T1DM, mechanisms of blood glucose regulation
during this type of exercise should be first examined in the healthy non-diabetic
population. With the exception of prolonged bouts of moderate intensity exercise (> 90
19
minutes in duration), non-diabetic individuals generally maintain euglycaemia
throughout moderate-intensity exercise and recovery (Brun et al., 2001). This is
achieved as a result of a precise match between the rate of endogenous glucose
production and the rate of glucose uptake by the tissues.
The onset of moderate-intensity exercise in non-diabetic individuals is accompanied by
a 2-fold increase in glucose uptake by the muscles (Davis et al., 2000c). This 2-fold
increase in glucose uptake by the exercising muscle would stimulate a decrease in blood
glucose if it were not matched by an equal increase in hepatic glucose production
(Davis et al., 2000c). Fortunately, a precisely matched increase in hepatic glucose
production occurs due to activation of both hepatic glycogenolysis and gluconeogenesis,
and euglycaemia is maintained as a result (Wolfe et al., 1986). This matching of glucose
production with glucose uptake continues into recovery from exercise until both glucose
production and glucose uptake return to basal levels (Wolfe et al., 1986). As a result, the
risk of an episode of hypoglycaemia during moderate-intensity exercise is minimal in
non-diabetic individuals.
The matching of glucose production to glucose uptake during exercise in non-diabetic
individuals is coordinated by the glucoregulatory hormones. The onset of moderate-
intensity exercise is accompanied by a decline in endogenous insulin secretion, which
decreases the level of circulating insulin usually responsible for stimulating glucose
uptake and inhibiting hepatic glucose production (Riddell & Perkins, 2006; Schneider et
al., 1991). This decrease in circulating insulin, which resulted from increased
sympathetic nervous system activity, sensitizes the liver to basal levels of the
counterregulatory hormones and thus enhances the effects they may have on blood
glucose regulation (Schneider et al., 1991). With a decline in insulin secretion, the
glucagon to insulin ratio increases regardless of whether the level of glucagon increases
or remains stable (Kjaer, 1992). As the duration of exercise increases, levels of
glucagon, catecholamines, growth hormone, and cortisol rise, resulting in increased
hepatic glucose output and further suppression of insulin secretion (Kjaer, 1992;
Kozlowski et al., 1979; Riddell & Perkins, 2006; Schneider et al., 1991). In short, the
counterregulatory hormones counteract the falling blood glucose caused by exercise-
mediated glucose uptake. The concentrations of the counterregulatory hormones are a
function of exercise intensity and duration, with greater increases as intensity and
duration increase (Kjaer, 1992; Kozlowski et al., 1979; Schneider et al., 1991). Insulin,
on the other hand, continues to change in the opposite direction, removing its inhibitory
20
effects on hepatic glucose production (Kjaer, 1992). The changes in insulin and
glucagon levels are primarily responsible for the maintenance of euglycaemia during
moderate-intensity exercise. The catecholamines have a secondary role, followed by
growth hormone and cortisol, which become increasingly important as the duration of
exercise is increased (Utter et al., 1999). Shortly after the onset of recovery, all
counterregulatory hormones return to baseline levels, with continued action from
growth hormone and cortisol as their release pattern and pharmacokinetics result in
long-term effects (Kjaer, 1992).
1.7.2 Regulation of Blood Glucose Levels during Moderate-Intensity Exercise in Individuals with Type 1 Diabetes
Moderate-intensity exercise in insulin-treated individuals with T1DM stimulates a
similar increase in glucose uptake by the muscles as that observed in non-diabetic
individuals (Simonson et al., 1984). However, insulin-treated individuals with T1DM
are unable to match this increase in glucose uptake with an equivalent increase in
hepatic glucose production as demonstrated by an increasing need for exogenous
glucose infusion during moderate-intensity exercise and early recovery performed under
a euglycaemic clamp (Guelfi et al., 2007b).
The mismatch between glucose uptake and hepatic glucose production during moderate-
intensity exercise in individuals with T1DM is largely the result of the inability of these
individuals to control their circulating insulin level (McMahon et al., 2007; Riddell &
Perkins, 2006; Wasserman & Zinman, 1994). Once exogenous insulin is given, its rate
of appearance and utilization is determined primarily by the pharmacokinetics of the
particular type of insulin administered. Therefore, unlike their non-diabetic
counterparts, individuals with T1DM are unable to decrease their circulating insulin
level in response to the onset of moderate-intensity exercise, leaving most individuals
hyperinsulinemic during exercise (McMahon et al., 2007; Wasserman & Zinman,
1994). This hyperinsulinemic state increases the risk of hypoglycaemia since there is an
additive effect of high levels of circulating insulin and muscle contraction on glucose
uptake by the muscles (Douen et al., 1990; Ivy, 1987). Also, high levels of circulating
insulin inhibit the rise in hepatic glucose production, despite the rise in the
counterregulatory hormones (Tuominen et al., 1995). As a result, the sustained elevation
21
in plasma insulin during exercise in individuals with T1DM causes a fall in blood
glucose during this type of activity (Guelfi et al., 2007a).
Further complicating blood glucose regulation during exercise, individuals with T1DM
are unable to mount a sufficient counterregulatory hormone response to the decline in
blood glucose (Rizza, et al., 1979). These individuals display insufficient increases in
norepinephrine and epinephrine during exercise, which play a key role in increasing
hepatic glucose output (McMahon et al., 2007; Schneider et al., 1991). Fortunately,
unlike during hypoglycaemia, glucagon responses are preserved during exercise in
individuals with T1DM, suggesting that the loss of the glucagon response is stimulus-
specific (Galassetti et al., 2003; Gerich et al., 1973). Like non-diabetic individuals,
glucagon is the primary counterregulatory hormone responsible for increases in hepatic
glucose production during this type of exercise (Shilo et al., 1990).
The combination of contraction-mediated glucose uptake, high levels of plasma insulin,
and insufficient counterregulatory hormone responses causes blood glucose to decline
during exercise, increasing the potential for hypoglycaemia (Galassetti et al., 2003;
Macdonald, 1987; McMahon et al., 2007; Peirce, 1999). The risk of hypoglycaemia
may be further increased since exercise can mask many of the symptoms signaling a
decline in blood glucose. For instance, tachycardia and sweating are two key responses
in both hypoglycaemia and exercise given that both forms of stress include high levels
of sympathetic outflow (Choi & Chisholm, 1996; Riddell & Bar-Or, 2002). When these
symptoms are detected during exercise, individuals with T1DM may wrongly attribute
them to the exercise as opposed to hypoglycaemia. Individuals with T1DM also tend to
overestimate their blood glucose when they are hypoglycaemic and underestimate their
level when they are hyperglycaemic (Riddell & Bar-Or, 2002). Therefore, regular blood
glucose monitoring is necessary during exercise for correct knowledge of blood glucose
levels.
Other factors, such as the timing of exercise in relation to the time of peak insulin
action, the specific location of injection site, and time of day, can also increase the risk
of hypoglycaemia. Exercising during the time of peak insulin action (i.e. within 2 hours
of a meal with an insulin bolus) increases the risk of hypoglycaemia since the additive
effect of insulin and exercise on blood glucose uptake is enhanced at this time (Colberg,
2000a). Insulin can also be injected in a variety of locations, such as the abdomen, arm,
buttocks, or thigh. If insulin is injected into an exercising limb, its absorption will be
22
faster due to increased blood flow to the area and a rise in body temperature (Choi &
Chisholm, 1996; Riddell & Perkins, 2006; Wasserman & Zinman, 1994). Therefore, if
exercise is planned, administration of insulin into a non-exercising body part (such as
the abdomen) is highly recommended. Time of day can also have a large impact on the
risk of hypoglycaemia because of circadian variations in the release of the
counterregulatory hormones. As a result of low levels of circulating exogenous insulin,
greater insulin resistance, and higher levels of cortisol, morning exercise, particularly
before breakfast and morning insulin, carries a lower risk of exercise-induced
hypoglycaemia than exercise performed later in the day (Colberg, 2000a; Colberg &
Swain, 2000). However, adjustments in insulin dosage and carbohydrate intake usually
still need to be made prior to participation in moderate-intensity exercise. A reduction in
insulin dosage, mimicking a healthy pancreas during exercise, decreases the risk of
hypoglycaemia, especially when exercise is performed postprandially (Colberg &
Swain, 2000; Lumb & Gallen, 2009; Riddell & Perkins, 2006). In addition, having
supplementary carbohydrates available during exercise is crucial as a means of treating
any hypoglycemic episodes that do occur (Colberg & Swain, 2000; Riddell et al., 1999).
Of note, moderate-intensity exercise also carries a heightened risk of hypoglycaemia for
up to 31 hours of recovery (Macdonald, 1987). The risk of hypoglycaemia during
recovery is especially increased both 60 to 90 minutes after exercise and several hours
later (Lumb & Gallen, 2009). Post-exercise late onset hypoglycaemia is a result of
increased glucose uptake to replenish glycogen stores (Macdonald, 1987; Peirce, 1999),
increased insulin sensitivity (Macdonald, 1987; Peirce, 1999), and impaired
counterregulation to hypoglycaemia after exercise (Macdonald, 1987). After an
exhausting bout of exercise, muscle glycogen stores are severely depleted and rely on
the uptake of blood glucose for re-synthesis. Consuming a large amount of carbohydrate
within 30 minutes of exercise provides a large carbohydrate supply from which muscle
glycogen can be re-synthesized, decreasing the reliance on the remaining blood glucose
and helping to prevent post-exercise late-onset hypoglycaemia (Colberg & Swain,
2000). Another factor that may increase the risk of hypoglycaemia after exercise is the
timing of the exercise session in relation to sleep. Counterregulatory hormone responses
to hypoglycaemia are highly impaired during sleep (Jones et al., 1998), and may
increase the risk of late-onset post-exercise hypoglycaemia when exercise is performed
in the late afternoon (McMahon et al., 2007). For these reasons, a reduction in basal
23
insulin is highly recommended after exercise to avoid hypoglycaemia during recovery
(Lumb & Gallen, 2009).
While less likely to occur, it is also possible for individuals with T1DM to exercise
while hypoinsulinemic. When circulating levels of insulin are low, blood glucose levels
rise and a state of hyperglycaemia ensues. An elevation in the counterregulatory
hormones as a result of the exercise further exacerbates the hyperglycaemia because of
an increase in hepatic glucose production. Although it may be tempting to commence
exercise with a higher blood glucose level, widening the range over which blood
glucose can safely decline, pre-exercise hypoinsulinaemia does not in fact help and
actually increases the risk of developing ketoacidosis (Colberg, 2000b; Lumb & Gallen,
2009; Riddell & Perkins, 2006). Also, hyperglycaemic conditions cause a shift towards
carbohydrate as a fuel during exercise, accelerating the decline in blood glucose during
exercise even further (Cryer et al., 2003). For these reasons, it is generally
recommended that blood glucose should be under 16.7 mM or 13.9 mM when in
combination with the presence of ketosis before exercise is started (American Diabetes
Association Position Statement, 2004).
1.8 Regulation of Blood Glucose Levels during High-Intensity Exercise and Recovery
It is often assumed that all intensities of exercise affect blood glucose levels in the same
manner. However, unlike moderate-intensity exercise, high-intensity exercise causes
blood glucose levels to rise in individuals both with and without diabetes. High-
intensity exercise is defined as exercise that is at or above 80% O2max or 75%
HRmax and has a rating of perceived exertion above 15 on the Borg scale (Grimm,
1999; Marliss & Vranic, 2002). High-intensity exercise includes sudden, intense
activities such as sprinting or exercise at or near maximal oxygen consumption (Colberg
& Swain, 2000).
24
1.8.1 Regulation of Blood Glucose Levels during High-Intensity Exercise in Non-Diabetic Individuals
In non-diabetic individuals, participation in 10 to 15 minutes of high-intensity exercise
(>80% O2max) is associated with a marked rise in blood glucose concentration
(Mitchell et al., 1988; Purdon et al., 1993). This rise in glycaemia is the result of an
imbalance between glucose production and glucose uptake, with a 7- to 8-fold increase
in the rate of hepatic glucose production, but only a 4-fold increase in the rate of
glucose uptake from the circulation (Marliss et al., 2000; Marliss & Vranic, 2002; Sigal
et al., 1994b). Since the rate of glucose production continually exceeds the rate of
glucose uptake, blood glucose continues to rise throughout exercise and early recovery,
resulting in transient hyperglycaemia (Kreisman et al., 2000; Mitchell et al., 1988;
Purdon et al., 1993, Sigal et al., 1994b). Of interest, short maximal sprint efforts of both
6 and 30-seconds in duration have also been shown to produce a marked rise in blood
glucose in non-diabetic individuals (Moussa et al., 2003).
Unlike moderate-intensity exercise, insulin and glucagon are not the key regulators of
the blood glucose response to high-intensity exercise. Rather, high-intensity exercise is
associated with a marked rise in the catecholamines, epinephrine and norepinephrine,
suggesting that they play an important role in blood glucose regulation during this type
of exercise (Kjaer, 1992; Lumb & Gallen, 2009; Marliss et al., 2000; Moussa et al.,
2003; Purdon et al., 1993). In comparison to the 2-fold increase in glucagon and the
slight, if any, increase in insulin, plasma norepinephrine and epinephrine levels increase
15-fold during high-intensity exercise (Kreisman et al., 2000; Kreisman et al., 2003;
Marliss et al., 2000; Sigal et al., 1994b). Therefore, it is unlikely that insulin and
glucagon contribute given their relative responses as well as their inappropriate timing
to explain the increase in glucose production (Kreisman et al., 2003; Marliss et al.,
2000; Purdon et al., 1993; Sigal et al., 1994b). In a study by Sigal and colleagues
(1996), a similar increase in glucose production was observed during high-intensity
exercise regardless of whether insulin and glucagon secretion were suppressed by
somatostatin and infused at basal levels, or allowed to respond as normal, suggesting
mechanisms other than the glucagon:insulin ratio control the glycaemic response to
high-intensity exercise. On the other hand, the rise in the catecholamines associated
with high-intensity exercise is significantly correlated with hepatic glucose production
(Kjaer, 1992; Kreisman et al., 2003; Purdon et al., 1993). To further support a role of
catecholamines in high-intensity exercise, Kreisman and colleagues (2003) infused high
25
levels of epinephrine and norepinephrine during moderate-intensity exercise to simulate
the hormonal response to high-intensity exercise. The result was a glycaemic response
similar to that seen in high-intensity exercise (Kreisman et al., 2003). In addition, it has
been shown that individuals who produce greater catecholamine responses to a given
level of high-intensity exercise display greater hyperglycaemia (Purdon et al., 1993).
The mechanism by which epinephrine and norepinephrine raise blood glucose levels
during high-intensity exercise involves the stimulation of hepatic glucose production via
the activation of glycogenolysis and gluconeogenesis, as well as the inhibition of
insulin-mediated glucose uptake by the tissues (Lumb & Gallen, 2009; Marliss et al.,
2000; Sigal et al., 1994b). These hormones operate in a feedforward manner without
any input from the rising blood glucose level (Marliss et al., 2000). Meanwhile, the high
levels of catecholamines inhibit insulin secretion, avoiding any potential effect insulin
may have on the rising blood glucose levels (Lumb & Gallen, 2009). The rise in the
catecholamines dominates and consequently glycaemia continues to rise (Riddell &
Perkins, 2006). However, it is important to note that not all studies necessarily support
a role for the catecholamines. Work performed using and receptor blockades has
shown that the increment in the glucose rate of appearance (Ra) during high-intensity
exercise was not dependent on adrenergic receptor stimulation (Coker et al., 1997;
Kjaer et al., 1993; Kjaer et al., 1995; Sigal et al., 1994a).
In non-diabetic individuals, recovery from high-intensity exercise is associated with an
initial increase in blood glucose, followed by a return to euglycaemia. By 10 minutes of
recovery, epinephrine and norepinephrine levels have declined by 80%, with a
subsequent fall in glucose production and rise in insulin secretion (Mitchell et al., 1988;
Sigal et al., 1994b). Likewise, glucagon, a potent stimulator of hepatic glucose
production during moderate-intensity exercise, returns to baseline within the first hour
of recovery, while growth hormone and cortisol, known for their long-term effects on
hepatic glucose production, rise during recovery from high-intensity exercise (Kraemer
et al., 2002; Pritzlaff et al., 2000). Of primary importance, insulin secretion reacts to the
high level of blood glucose and lower levels of circulating catecholamines, by nearly
doubling the circulating level of insulin (Purdon et al., 1993; Sigal et al., 1994b). This
hyperinsulinemic state accelerates glucose uptake by the tissues to rapidly replenish
muscle glycogen stores, causing glucose uptake to surpass glucose production and
return blood glucose levels to normal within 40 minutes of recovery (Lumb & Gallen,
2009; Purdon et al., 1993; Riddell & Perkins, 2006).
26
1.8.2 Regulation of Blood Glucose Levels during High-Intensity Exercise in Individuals with Type 1 Diabetes
High-intensity exercise (10-15 minutes at >80% O2max) produces a similar
glycaemia-increasing effect in individuals with T1DM (Moussa et al., 2003; Purdon et
al., 1993). Like non-diabetic individuals, the continued rise in glycaemia associated
with high-intensity exercise in individuals with T1DM is the result of a disproportionate
increase in glucose production relative to that of glucose uptake (Purdon et al., 1993;
Sigal et al., 1994b). The proposed mechanism underlying this disproportionate increase
in glucose production relative to glucose uptake is a 15-fold increase in the
concentrations of the catecholamines, epinephrine and norepinephrine (Colberg, 2000a;
Deibert & DeFronzo, 1980; Kreisman et al., 2003; Nonogaki, 2000; Purdon et al.,
1993). On the other hand, glucagon levels remain unchanged (Hübinger et al., 1985;
Mitchell et al., 1988) or increase slightly (Purdon et al., 1993; Sigal et al., 1994b) during
this type of exercise. Furthermore, high-intensity exercise elicits similar rises in cortisol
and growth hormone as in non-diabetic individuals (Hübinger et al., 1985, Purdon et al.,
1993). The similarity in the glycemic response to high-intensity exercise between
individuals with T1DM and non-diabetic individuals is consistent with the relative
unimportance of plasma insulin in the glycaemic response to this type of exercise.
However, a marked difference exists between non-diabetic individuals and those with
T1DM in the glycaemic response during recovery from high-intensity exercise. Within
a few minutes of the onset of recovery, catecholamine levels return to baseline and
hepatic glucose production declines as a result (Sigal et al., 1994b). At this point,
plasma insulin secretion begins to rise in non-diabetic individuals, stimulating glucose
uptake, glycogen re-synthesis, and the return of blood glucose to euglycaemic levels.
However, individuals with T1DM are unable to control the level of circulating insulin
and, as a result, are unable to mount a rise in circulating insulin in response to the
existing hyperglycaemia (Purdon et al., 1993; Riddell & Perkins, 2006; Wasserman &
Zinman, 1994). Consequently, insulin-mediated glucose uptake does not increase and
the hyperglycaemic state persists well into recovery (Mitchell et al., 1988; Purdon et al.,
1993; Sigal et al., 1994b). The role of insulin in recovery from high-intensity exercise is
supported by a study by Marliss & Vranic (2002), in which insulin was infused into
individuals with T1DM throughout high-intensity exercise and early recovery. The level
of infused insulin was doubled during recovery in one group and kept constant in the
other. It was found that doubling the insulin infusion rate during recovery restored
27
euglycaemia in individuals with T1DM. However, the glycaemic decline in these
individuals often started from a higher blood glucose level and declined slower than in
non-diabetic individuals, indicating the importance of an acute insulin response in
restoring euglycaemia (Marliss & Vranic, 2002). In the constant insulin infusion group,
the increase in blood glucose persisted for the 2-hour recovery period. Overall, the
inability of individuals with T1DM to increase the level of circulating insulin post-
exercise translates into a sustained increase in blood glucose during recovery from high-
intensity exercise, thereby decreasing the risk of post-exercise hypoglycaemia in
individuals with T1DM after high-intensity exercise, unlike moderate-intensity exercise
(Purdon et al., 1993). However, the effect of high-intensity exercise on late-onset post-
exercise hypoglycaemia, which occurs several hours later, has yet to be established.
1.9 Clinical Implications of High-Intensity Exercise as a Tool to Reduce the Risk of Hypoglycaemia
The glycaemia-increasing effect of high-intensity exercise may provide a promising tool
for decreasing the risk of hypoglycaemia in individuals with T1DM. However,
continuous high-intensity exercise above 80% O2max lasting 10 to 15 minutes may
be too strenuous for the majority of the T1DM population, which limits its application
in practice. For this reason, the effect of a much shorter bout of maximal intensity
exercise on blood glucose levels was recently investigated in this population. Harmer
and colleagues (2006) demonstrated that high-intensity exercise at 130% O2max,
lasting approximately 78 ± 21 seconds, causes a transient increase in blood glucose
levels throughout exercise and recovery in individuals with T1DM. However, since a
10-second sprint is generally better tolerated by the majority of individuals, Bussau and
colleagues (2006) examined the glycaemic response to a 10-second maximal sprint
performed immediately following the completion of 20 minutes of moderate-intensity
exercise in individuals with T1DM. These researchers reported that adding the 10-
second sprint to the end of a bout of moderate-intensity exercise opposed a further
decline in blood glucose levels for 120 minutes of recovery, despite plasma insulin
being well above basal levels. This stabilization of blood glucose levels during recovery
was partially explained by a marked rise in the catecholamines, growth hormone, and
cortisol resulting from the sprint (Bussau et al., 2006). Building upon these results,
28
Bussau and colleagues (2007) performed a further study to investigate whether
performing a 10-second sprint immediately before a 20-minute bout of moderate-
intensity exercise would have the same effect. It was found that although sprinting had
no effect on the decline in blood glucose levels during subsequent moderate-intensity
exercise, the sprint did prevent blood glucose levels from falling for at least the first 45
minutes of recovery after the exercise (Bussau et al., 2007). Once again, the
stabilization of blood glucose was attributed to the increased norepinephrine levels in
conjunction with increased lactate levels from the sprint.
The risk of hypoglycaemia during and after moderate-intensity exercise may also be
reduced by performing repeated short maximal sprints throughout continuous moderate-
intensity exercise (Guelfi et al., 2005). In a study by Guelfi and colleagues (2005),
individuals with T1DM performed either 30 minutes of moderate-intensity activity at
40% O2peak either with or without the addition of 4-second sprints every 2 minutes.
The results showed that blood glucose declined significantly less during moderate-
intensity exercise that included repeated short sprints compared to moderate-intensity
exercise alone. This provides further support for the need to develop better exercise
guidelines as small transient differences in exercise intensity and duration occur
regularly and without intent in reality, and can evidently have an impact on
glucoregulation. Furthermore, blood glucose levels remained stable during recovery
from moderate-intensity exercise with repeated short sprints, while levels continued to
decline after moderate-intensity exercise alone (Guelfi et al., 2005). This attenuated
decrease in blood glucose level when adding repeated short sprints to moderate-
intensity exercise was associated with a significantly greater increase in growth
hormone and norepinephrine with this type of exercise (Guelfi et al., 2005). These
hormonal changes were associated with a more rapid and greater increment in Ra,
together with a more rapid decline in the rate of peripheral glucose disposal (Rd) in early
recovery from this type of exercise (Guelfi et al., 2007b).
Taken together, these findings indicate that one or many short maximal sprints
performed before, during, or after moderate-intensity exercise may reduce the risk of
hypoglycaemia during early recovery in individuals with T1DM. This highlights the
potential usefulness of short sprints as an additional tool to prevent hypoglycaemia
associated with exercise. Accordingly, this could possibly be a preferred method of
raising blood glucose levels for competitive athletes when carbohydrate is not available
or they do not wish to stop exercising.
29
1.10 Factors that May Influence the Glycaemia-Increasing Effect of a Sprint in Individuals with Type 1 Diabetes
The discovery that a short sprint may provide a possible tool to decrease the risk of
hypoglycaemia is very promising for the development of improved exercise guidelines
for individuals with T1DM. However, more extensive research needs to be performed
to identify potential factors that could impair the glycaemic benefit of a sprint so that
safe and accurate guidelines can be given. For example, it has been shown that a prior
bout of hypoglycaemia diminishes the counterregulatory hormone responses to a
subsequent bout of moderate-intensity exercise in individuals with T1DM (Galassetti et
al., 2003). Moreover, bouts of antecedent moderate-intensity exercise have been shown
to blunt the counterregulatory hormone responses to both future hypoglycaemia
(Galassetti et al., 2001a; Sandoval et al., 2004) and moderate-intensity exercise,
impairing the glycaemic response to these events (Galassetti et al., 2001b). Since the
catecholamines play a central role in the glycaemic benefit of a sprint, it is possible that
antecedent hypoglycaemia and moderate-intensity exercise may also impair the
counterregulatory hormone response and glycaemic benefit of sprinting.
1.10.1 Influence of Antecedent Hypoglycaemia
An acute bout of hypoglycaemia has been shown to diminish the counterregulatory
response to a subsequent bout of moderate-intensity exercise in both non-diabetic
individuals (Davis et al., 2000b) and individuals with T1DM (Galassetti et al., 2003).
Davis and colleagues (2000b) demonstrated that two episodes of antecedent moderate
hypoglycaemia reduced the counterregulatory hormone responses to moderate-intensity
exercise performed the following day by 50% in non-diabetic individuals. More
specifically, they observed blunted epinephrine, norepinephrine, glucagon, growth
hormone, and cortisol responses compared to the same exercise performed following
two episodes of antecedent euglycaemia (Davis et al., 2000b). Likewise, antecedent
hypoglycaemia has been shown to blunt the counterregulatory hormone responses to a
subsequent bout of moderate-intensity exercise performed by individuals with T1DM
(Galassetti et al., 2003). In response to 90-minutes of moderate-intensity exercise
following two 2-hour periods of hypoglycaemia on the previous day, individuals with
30
T1DM showed a reduced glucagon response in addition to attenuated epinephrine,
norepinephrine, and cortisol responses that were blunted by 40-80% compared to an
antecedent euglycaemia condition (Galassetti et al., 2003).
The proposed explanation for the blunting of the counterregulatory responses caused by
antecedent hypoglycaemia is a reduction in the ANS drive to the pancreas, adrenal
gland, and sympathetic nerve endings. A series of studies have suggested that an
increase in cortisol can reduce the neuroendocrine and ANS counterregulatory
responses to a variety of subsequent stressors (Brown & Fisher, 1986; Davis et al.,
1996; Komesaroff & Funder, 1994; Udelsman et al., 1987). As evidence for this, one
study infused participants with a level of cortisol that mimicked the cortisol rise during
hypoglycaemia before measuring the responses to hypoglycaemia on the following day
(Davis et al., 1996). When compared to the antecedent euglycaemia and hypoglycaemia
groups, ANS responses were similarly blunted after the infused cortisol and the
antecedent hypoglycaemia (Davis et al., 1996). Since this blunting occurs in the
counterregulatory hormone response, it is possible that other stressors that increase the
level of cortisol (i.e. moderate-intensity exercise) may also affect any subsequent events
that rely on a counterregulatory hormone response. Since the glycaemic benefit of a
sprint is likely to be mediated by an increase in catecholamine levels, a bout of
antecedent hypoglycaemia, which raises the cortisol levels, could potentially blunt the
catecholamine response to a short sprint and reduce the glycaemic benefit of the sprint.
However, it is important to note that not all studies support a role for cortisol in the
blunting caused by antecedent stressors (Goldberg et al., 2006; Raju et al., 2003).
1.10.2 Influence of Antecedent Exercise
Another factor that may influence the glycaemic benefit of a sprint is prior exercise. Of
interest, a single bout of moderate-intensity exercise has been shown to cause
significant blunting of the counterregulatory response to a subsequent moderate-
intensity exercise bout. In a study performed by Galassetti and colleagues (2001b), non-
diabetic participants were either required to rest or complete a 90-minute bout of
exercise at 50% O2max, followed by a 3-hour break and then a subsequent 90-minute
exercise bout at the same intensity. Reduced epinephrine, norepinephrine, cortisol, and
growth hormone responses were observed during the second exercise bout following
31
antecedent exercise (Galassetti et al., 2001b). In addition, the glucose infusion rate
required to maintain euglycaemia was almost 5 times greater during the second exercise
bout after antecedent exercise compared to when no prior exercise was performed,
suggesting that endogenous glucose production was substantially lower following a
prior bout of moderate-intensity exercise.
Furthermore, Galassetti and colleagues (2001b) investigated gender differences in the
effect of an antecedent bout of exercise on the counterregulatory responses to a second
bout of exercise. Individuals without diabetes exercised for 90-minutes at 80% of
anaerobic threshold followed by a 3-hour break before a second identical bout of
exercise was performed. During the first bout of exercise, men showed a greater
counterregulatory response than women, attaining significantly higher absolute levels of
epinephrine, norepinephrine, cortisol, and growth hormone in response to moderate-
intensity exercise (Galassetti et al., 2001b). It has been suggested that this is a reflection
of women displaying a greater sensitivity to ANS drive (Davis et al., 1993). However,
during the second exercise bout, men had reduced epinephrine, norepinephrine, cortisol,
and growth hormone responses compared to their previous bout (Galassetti et al.,
2001b). In contrast, the counterregulatory responses to exercise were unchanged or
increased in women when compared to their first bout of exercise, leading to a
statistically significant gender difference in the change of these parameters between the
two exercise bouts (Galassetti et al., 2001b). So although men had greater
counterregulatory responses to the first bout of exercise, they experienced significantly
greater blunting than women during the second bout of exercise.
Since antecedent moderate-intensity exercise is known to reduce the catecholamine
response to subsequent moderate-intensity exercise, it is possible that antecedent
exercise may similarly reduce the catecholamine response, and therefore the glycaemia-
increasing response, to a subsequent sprint. Whether the glycaemia-increasing response
to a subsequent maximal sprint is blunted by antecedent exercise has yet to be
determined. This may have implications for the efficacy of sprinting as a safe and
reliable means to reduce the risk of exercise-mediated hypoglycaemia.
32
1.11 Summary
Treatment of T1DM involves balancing diet and administered insulin in order to
achieve acceptable blood glucose levels. In spite of this, many individuals with T1DM
lead full, normal lives and participate in many of the same activities as individuals
without diabetes. Exercise is one such activity, with regular exercise affording
numerous health benefits to both the healthy and T1DM populations. However, it must
be acknowledged that exercise does complicate management of blood glucose levels. It
is well established that different intensities of exercise have different effects on blood
glucose levels and that certain types of exercise may increase the risk of
hypoglycaemia. Moderate-intensity exercise causes blood glucose levels to continually
decline during exercise and recovery, increasing this risk of hypoglycaemia, a
potentially life threatening condition. In contrast, high-intensity exercise has been
shown to raise blood glucose levels. In fact, a maximal sprint effort as short as 10
seconds can delay the decline of blood glucose during exercise and short-term recovery.
This suggests that a short maximal sprint may be a promising tool for decreasing the
risk of exercise-mediated hypoglycaemia in individuals with T1DM. However, before
sprinting can be safely and accurately added to clinical exercise guidelines, factors that
may impair the efficacy of a sprint need to be investigated. Therefore, the purpose of
this thesis was to investigate whether a bout of antecedent moderate-intensity exercise
attenuates the glycaemia-increasing as well as the counterregulatory hormone response
to a short maximal sprint performed hours later in non-diabetic individuals. Non-
diabetic individuals were studied in order to firstly understand how antecedent exercise
influences the glycaemia-increasing effect of sprinting under non-pathological
conditions.
1.12 Aims
The primary goal of this thesis was to investigate the effect of an antecedent exercise
bout on the blood glucose and counterregulatory hormone response to a short, maximal
sprint in non-diabetic individuals. A short, maximal sprint has been recommended as a
tool in the prevention of exercise-induced hypoglycaemia; however, factors that may
33
alter its efficacy must be established before safe and accurate guidelines can be given.
The objective of this study was to investigate whether antecedent exercise affects the
glycaemia-increasing effect of sprinting in non-diabetic individuals. The information
obtained will form the basis for future research on individuals with T1DM.
1.13 Research Hypotheses
The hypotheses relating to these aims were that;
- 60 minutes of antecedent moderate intensity exercise (65% O2max) would reduce
the glycaemia-increasing effect of a 30-second maximal sprint performed 3 hours
later
- This predicted reduced glycaemia-increasing response after antecedent exercise
would be associated with blunted counterregulatory responses to the maximal
sprint.
1.14 Significance of the Study
The use of a short maximal sprint has been proposed as a tool to reduce the risk of
hypoglycaemia in individuals with T1DM; accordingly, this study will highlight
whether this benefit persists after antecedent exercise. The results of this study will
form the basis for future studies on individuals with T1DM and may have implications
for existing guidelines for exercise for these individuals.
34
1.15 References
American College of Sports Medicine. (1998). The recommended quantity and quality
of exercise for developing and maintaining cardiorespiratory and muscular fitness,
and flexibility in healthy adults. Medicine & Science in Sports & Exercise, 30(6),
975-991.
American Diabetes Association. (1997). Diabetes mellitus and exercise: Joint position
paper. Medicine and Science in Sports & Exercise, 29, 1-6.
American Diabetes Association. (1999). Diabetes mellitus and exercise. Diabetes Care,
22, S49-S53.
American Diabetes Association. (2011). Ketoacidosis (DKA). Retrieved July 2, 2011,
from http://www.diabetes.org/living-with-diabetes/complications/ketoacidosis-
dka.html
American Diabetes Association Position Statement. (2004). Physical activity/exercise
and diabetes. Diabetes Care, 27, S58-S62.
American Diabetes Association Position Statement. (2011). Standards of medical care
in diabetes – 2011. Diabetes Care, 34, S11-S61.
Amiel, S.A., Maran, A., Powne, J., Umpleby, A., & Macdonald, I. (1993). Gender
differences in counterregulation to hypoglycaemia. Diabetologia, 36, 460-464.
Amiel, S.A., Sherwin, R.S., Simonson, D.C., & Tamborlane, W.V. (1988). Effect of
intensive insulin therapy on glycemic thresholds for counterregulatory hormone
release. Diabetes, 37, 901-907.
Australian Diabetes Council. (2010). Quick Facts. Retrieved March 13, 2011, from
http://www.australiandiabetescouncil.com/About-Diabetes/Quick-facts.aspx
Bao, S., Briscoe, V.J., Tate, D.B., & Davis, S.N. (2009). Effects of differing antecedent
increases of plasma cortisol on counterregulatory responses during subsequent
exercise in type 1 diabetes. Diabetes, 58, 2100-2108.
Bliss, M. (1993). The history of insulin. Diabetes Care, 16(Suppl 3), 4-7.
35
Bolli, G.B. (1990). From physiology of glucose counterregulation to prevention of
hypoglycaemia in type 1 diabetes mellitus. Diabetes Nutrition and Metabolism, 3,
333-349.
Bolli, G.B. (2003). Treatment and prevention of hypoglycaemia and its unawareness in
type 1 diabetes mellitus. Reviews in Endocrine and Metabolic Disorders, 4(4),
335-341.
Bolli, G.B., De Feo, P., Compagnucci, P., Cartechini, M.G., Angeletti, G., Santeusanio,
F., Brunetti, P., & Gerich, J.E. (1983). Abnormal glucose counterregulation in
insulin-dependent diabetes mellitus: interaction of anti-insulin antibodies and
impaired glucagon and epinephrine secretion. Diabetes, 32, 134-141.
Bolli, G.B., Dimitriadis, G.D., Pehling, G.B., Baker, B.A., Haymond, M.W., Cryer,
P.E., & Gerich, J.E. (1984). Abnormal glucose counterregulation after
subcutaneous insulin in insulin-dependent diabetes mellitus. The New England
Journal of Medicine, 310(26), 1706-1711.
Boyle, P.J., & Cryer, P.E. (1991). Growth hormone, cortisol, or both are involved in
defence against, but are not critical to recovery from, hypoglycaemia. American
Journal of Physiology – Endocrinology and Metabolism, 260, E395-E402.
Boyle, P.J., Shah, S.D., & Cryer, P.E. (1989). Insulin, glucagon, and catecholamines in
prevention of hypoglycaemia during fasting. American Journal of Physiology –
Endocrinology and Metabolism, 256, E651-E661.
Brown, M.R., & Fisher, L.A. (1986). Glucocorticoid suppression of the sympathetic
nervous system and adrenal medulla. Life Sciences, 39, 1003-1012.
Brun, J.F., Dumortier, M., Fedou, C., & Mercier, J. (2001). Exercise hypoglycaemia in
nondiabetic subjects. Diabetes & Metabolism, 27(2), 92-106.
Bussau, V.A., Ferreira, L.D., Jones, T.W., & Fournier, P.A. (2006). The 10-s maximal
sprint: A novel approach to counter an exercise-mediated fall in glycaemia in
individuals with type 1 diabetes. Diabetes Care, 29(3), 601-606.
36
Bussau, V.A., Ferreira, L.D., Jones, T.W., & Fournier, P.A. (2007). A 10-s sprint
performed prior to moderate-intensity exercise prevents early post-exercise fall in
glycaemia in individuals with type 1 diabetes. Diabetologia, 50, 1815-1818.
Cherrington, A.D., Edgerton, D., & Sindelar, D.K. (1998). Direct and indirect effects of
insulin on hepatic glucose production in vivo. Diabetologia, 41, 987-996.
Chiarelli, F., Dahl-Jorgensen, K., & Kiess, W. (2005). Diabetes in childhood and
adolescence. Basel, Switzerland: Karger Publishers.
Chiarelli, F., Verotti, A., Catino, M., Sabatino, G., & Pinelli, L. (1999). Hypoglycaemia
in children with type 1 diabetes mellitus. Acta Paediatrica Supplement, 427, 31-
34.
Choi, K., & Chisholm, D.J. (1996). Exercise and insulin-dependent diabetes mellitus
(T1D): Benefits and pitfalls. Australian and New Zealand Journal of Medicine,
26(6), 827-833.
Coker, R.H., Krishna, M.J., Lacey, D.B., Bracy, D.P., & Wasserman, D.H. (1997). Role
of hepatic - and -adrenergic receptor stimulation on hepatic glucose production
during heavy exercise. American Journal of Physiology – Endocrinology and
Metabolism, 273, E831-E838.
Colberg, S.R. (2000a). Practical management of type 1 diabetes during exercise. The
Journal of Physical Education, Recreation, and Dance, 71(2), 24-27.
Colberg, S.R. (2000b). Use of clinical practice recommendations for exercise by
individuals with type 1 diabetes. The Diabetes Educator, 26(2), 265-271.
Colberg, S.R., & Swain, D.P. (2000). Exercise and diabetes control: A winning
combination. The Physician and Sportsmedicine, 28(4), 63-81.
Cryer, P.E., Davis, S.N., & Shamoon, H. (2003). Hypoglycaemia in diabetes. Diabetes
Care, 26(6), 1902-1912.
Dagogo-Jack, S.E., Craft, S., & Cryer, P.E. (1993). Hypoglycemia-associated
autonomic failure in insulin-dependent diabetes mellitus. Journal of Clinical
Investigations, 91, 819-828.
37
Davis, S.N., Cherrington, A.D., Goldstein, R.E., Jacobs, J., & Price, L. (1993). Effects
of insulin on the counterregulatory response to equivalent hypoglycaemia in
normal females. American Journal of Physiology – Endocrinology and
Metabolism, 265, E680-E689.
Davis, S.N., Fowler, S., & Costa, F. (2000a). Hypoglycemic counterregulatory
responses differ between men and women with type 1 diabetes. Diabetes, 49(1),
65-72.
Davis, S.N., Galassetti, P., Wasserman, D.H., & Tate, D. (2000b). Effects of antecedent
hypoglycaemia on subsequent counterregulatory responses to exercise. Diabetes,
49, 73-81.
Davis, S.N., Galassetti, P., Wasserman, D.H., & Tate, D. (2000c). Effects of gender on
neuroendocrine and metabolic counterregulatory responses to exercise in
normal man. The Journal of Clinical Endocrinology and Metabolism, 85(1),
224-230.
Davis, S.N., Shavers, C., & Costa, F. (2000d). Gender-related differences in
counterregulatory responses to antecedent hypoglycaemia in normal humans.
Journal of Clinical Endocrinology and Metabolism, 85, 2148-2157.
Davis, S.N., Shavers, C., Costa, F., & Mosqueda-Garcia, R. (1996). Role of cortisol in
the pathogenesis of deficient counterregulation after antecedent hypoglycaemia in
normal humans. Journal of Clinical Investigations, 98, 680-691.
Davis, S.N., Shavers, C., Mosqueda-Garcia, R., & Costa, F. (1997). Effects of differing
antecedent hypoglycemia on subsequent counterregulation in normal humans.
Diabetes, 46, 1328-1335.
Dawson, T. (2002). Managing an athlete with diabetes. New Zealand Journal of Sports
Medicine, 30(1), 26-28.
De Feo, P., Perriello, G., Torlone, E., Ventura, M.M., Santeusanio, F., Brunetti, P.,
Gerich, J.E., & Bolli, G.B. (1989a). Demonstration of a role for growth hormone
in glucose counterregulation. American Journal of Physiology – Endocrinology
and Metabolism, 256, E835-E843.
38
De Feo, P., Perriello, G., Torlone, E., Ventura, M.M., Fanelli, C., Santeusanio, F.,
Brunetti, P., Gerich, J.E., & Bolli, G.B. (1989b). Contribution of cortisol to
glucose counterregulation in humans. American Journal of Physology –
Endocrinology and Metabolism, 257, E35-E42.
Deibert, D.C., & DeFronzo, R.A. (1980). Epinephrine-induced insulin resistance in
man. Journal of Clinical Investigations, 65, 717-721.
Diamond, M.P., Jones, T., Caprio, S., Hallarman, L., Diamond, M.C., Addabbo, M.,
Tamborlane, W.V., & Sherwin, R.S. (1993). Gender influences counterregulatory
hormones responses to hypoglycaemia. Metabolism, 42, 1568-1572.
Dobbins, R.L., Davis, S.N., Neal, D., Caumo, A., Cobelli, C., & Cherrington, A.D.
(1998). Rates of glucagon activation and deactivation of hepatic glucose
production in conscious dogs. Metabolism, 47, 135-142.
Douen, A.G., Ramlal, T., Rastogi, S., Bilan, P.J., Cartee, G.D., Vranic, M., Holloszy,
J.O., & Klip, A. (1990). Exercise induces recruitment of the “insulin-responsive
glucose transporter”. The Journal of Biological Chemistry, 265(23), 13427-13430.
Draznin, M.B. (2000). Type 1 diabetes and sports participation strategies: Strategies for
training and competing safely. The Physician and Sportsmedicine, 28(12), 49-56.
Draznin, M.B. (2010). Managing the adolescent athlete with type 1 diabetes mellitus.
Pediatric Clinics of North America, 57, 829-837.
Ertl, A.C., & Davis, S.N. (2004). Evidence for a vicious cycle of exercise and
hypoglycaemia in type 1 diabetes mellitus. Diabetes/Metabolism Research and
Reviews, 20, 124-130.
Fanelli, C.G., Epifano, L., Rambotti, A.M., Pampanelli, S., Di Vincenzo, A., Modarelli,
F., Lepore, M., Annibale, B., Ciofetta, M., Bottini, P., et al. (1993). Meticulous
prevention of hypoglycaemia normalizes the glycemic thresholds and magnitude
of most of neuroendocrine responses to, symptoms of, and cognitive function
during hypoglycaemia in intensively treated patients with short-term IDDM.
Diabetes, 42(11), 1683-1689.
39
Fonjallaz, P., & Loumaye, E. (2000). Glucagon rDNA origin (GlucaGen) and
recombinant LH. Journal of Biotechnology, 75, 185-189.
Galassetti, P., Mann, S., Tate, D., Neill, R.A., Costa, F., Wasserman, D.H., & Davis,
S.N. (2001a). Effects of antecedent prolonged exercise on subsequent
counterregulatory responses to hypoglycaemia. American Journal of Physiology –
Endocrinology and Metabolism, 280, E908-E917.
Galassetti, P., Mann, S., Tate, D., Neill, R.A., Wasserman, D.H., & Davis, S.N.
(2001b). Effect of morning exercise on counterregulatory responses to
subsequent, afternoon exercise. Journal of Applied Physiology, 91(1), 91-99.
Galassetti, P., Tate, D., Neill, R.A., Morrey, S., Wasserman, D.H., & Davis, S.N.
(2003). Effect of antecedent hypoglycaemia on counterregulatory responses to
subsequent euglycemic exercise in type 1 diabetes. Diabetes, 52, 1761-1769.
Gerich, J.E., Langlois, M., Noacco, C., Karam, J.H., & Forsham, P.H. (1973). Lack of
glucagon response to hypoglycaemia in diabetes: Evidence for an intrinsic
pancreatic alpha cell defect. Science, 182, 171-173.
Goldberg, P., Weiss, R., McCrimmon, R., Hintz, E., Dziura, J., & Sherwin, R.S. (2006).
Antecedent hypercortisolemia is not primarily responsible for generating
hypoglycemia-associated autonomic failure. Diabetes, 55, 1121-1126.
Goldstein, R.E., Abumrad, N.N., Lacy, D.B., Wasserman, D.H., & Cherrington, A.D.
(1995). Effects of an acute increase in epinephrine and cortisol on carbohydrate
metabolism during insulin deficiency. Diabetes, 44, 672-681.
Gosmanov, N.R., Szoke, E., Israelian, Z., Smith, T., Cryer, P.E., Gerich, J.E., & Meyer,
C. (2005). Role of the decrement in intraislet insulin for the glucagon response to
hypoglycaemia in humans. Diabetes Care, 28, 1124-1131.
Greene, D.A., Sima, A.A.F., Stevens, M.J., Feldman, E.L., & Lattimer, S.A. (1992).
Complications: Neuropathy, pathogenetic considerations. Diabetes Care, 15(12),
1902-1925.
Grimm, J.J. (1999). Exercise in type 1 diabetes. In B. Burr & D. Nagi (Eds.), Exercise
and sport in diabetes (pp 25-44). Chichester, NY: Wiley.
40
Guelfi, K.J., Jones, T.W., & Fournier, P.A. (2005). The decline in blood glucose levels
is less with intermittent high-intensity compared with moderate exercise in
individuals with type 1 diabetes. Diabetes Care, 28(6), 1289-1294.
Guelfi, K.J., Jones, T.W., & Fournier, P.A. (2007a). New insights into managing the
risk of hypoglycaemia associated with intermittent high-intensity exercise in
individuals with type 1 diabetes mellitus. Sports Medicine, 37(11), 937-946.
Guelfi, K.J., Ratnam, N., Smythe, G.A., Jones, T.W., & Fournier, P.A. (2007b). Effect
of intermittent high-intensity compared with continuous moderate exercise on
glucose production and utilization in individuals with type 1 diabetes. American
Journal of Physiology – Endocrinology and Metabolism, 292, E865-E870.
Haymond, M.W., & Schreiner, B. (2001). Mini-dose glucagon rescue for
hypoglycaemia in children with type 1 diabetes. Diabetes Care, 24, 643-645.
Heller, S.R., & Cryer, P.E. (1991). Reduced neuroendocrine and symptomatic responses
to subsequent hypoglycemia after one episode of hypoglycemia in nondiabetic
humans. Diabetes, 40, 223-226.
Henquin, J-C. (2000). Triggering and amplifying pathways of regulation of insulin
secretion by glucose. Diabetes, 49, 1751-1760.
Hornsby, W.G., & Albright, A.L. (2009). Diabetes. In American College of Sports
Medicine (Eds.), ACSM’s exercise management for persons with chronic diseases
and disabilities (pp 182-191). USA: Human Kinetics.
Hübinger, A., Ridderskamp, I., Lehmann, E., & Gries, F.A. (1985). Metabolic response
to different forms of physical exercise in type 1 diabetes and the duration of the
glucose lowering effect. European Journal of Clinical Investigation, 15, 197-203.
Ivy, J.L. (1987). The insulin-like effect of muscle contraction. Exercise and Sport
Science Reviews, 15, 29-51.
Jabbour, S. (2007). Type 1 diabetes in adults: Principles and practice. New York:
Informa Healthcare
41
Jiang, G., & Zhang, B.B. (2003). Glucagon and regulation of glucose metabolism.
American Journal of Physiology - Endocrinology, and Metabolism, 284, E671-
E678.
Jones, T.W., Porter, P., Sherwin, R.S., Davis, E.A., O’Leary, P., Frazer, F., Byrne, G.,
Stick, S., & Tamborlane, W.V. (1998). Decreased epinephrine responses to
hypoglycaemia during sleep. The New England Journal of Medicine, 338(23),
1657-1662.
Juvenile Diabetes Research Foundation. (2006). What is Type 1 Diabetes? Retrieved
March 13, 2011, from http://www.jdrf.org.au/living-with-type-1-diabetes/what-is-
type-1-diabetes
Juvenile Diabetes Research Foundation. (2010a). Diabetes Fact Sheet- What is Type 1
Diabetes? Retrieved March 13, 2011, from
http://www.jdrf.org.au/s/media/documents/jdrf_fact_sheet_-
_what_is_type_1_diabetes.pdf
Juvenile Diabetes Research Foundation. (2010b). Type 1 Diabetes Complications.
Retrieved March 13, 2011, from http://www.jdrf.org.au/living-with-type-1-
diabetes/type-1-diabetes-complications
Kanaley, J.A., & Hartman, M.L. (2002). Cortisol and growth hormone responses to
exercise. The Endocrinologist, 12, 421-432.
Kaufman, F.R., Gibson, L.C., Halvorson, M., Carpenter, S., Fisher, L.K., &
Pitukcheewanont, P. (2001). A pilot study of the continuous glucose monitoring
system. Diabetes Care, 24(12), 2030-2034.
Khardori, R. (2011). Type 1 Diabetes Mellitus: Epidemiology. Retrieved October 6,
2011, from http://emedicine.medscape.com/article/117739-overview#a0156
Kitabchi, A.E., Umpierrez, G.E., Murphy, M.B., Barrett, E.J., Kreisberg, R.A., Malone,
J.I., and Wall, B.M. (2001). Management of hyperglycaemic crises in patients
with diabetes. Diabetes Care, 24, 131-153.
Kjaer, M. (1992). Regulation of hormonal and metabolic responses during exercise in
humans. Exercise and Sport Sciences Reviews, 20, 161-184.
42
Kjaer, M., Engfred, K., Fernandez, A., Secher, N., & Galbo, H. (1993). Regulation of
hepatic glucose production during exercise in humans: role of
sympathoadrenergic activity. American Journal of Physiology – Endocrinology
and Metabolism, 265(28), E275-E283.
Kjaer, M., Keiding, S., Engfred, K., Rasmussen, K., Sonne, B., Kirkegard, P., & Galbo,
H. (1995). Glucose homeostasis during exercise in humans with a liver or kidney
transplant. American Journal of Physiology – Endocrinology and Metabolism,
268(31), E636-E644.
Klabunde, R.E. (2008, June 17). Cardiovascular physiology: circulating catecholamines.
Retrieved fromhttp://www.cvphysiology.com/Blood%20Pressure/BP018.htm
Komesaroff, P.A., & Funder, J.W. (1994). Differential glucocorticoid effects on
catecholamine responses to stress. American Journal of Physiology, 266, E118-
E128.
Kozlowski, S., Brzezinska, Z., & Nazar, K. (1979). Diminished adrenergic response to
2-deoxy-D-glucose after prolonged, exhausting physical exercise in dogs. Acta
Physiologica Polonica, 30(3), 331-335.
Kraemer, R.R., Chu, H., & Castracane, V.D. (2002). Leptin and exercise. Bulletin of
Experimental Biology & Medicine, 227, 701-708.
Kreisman, S.H., Ah Mew, N., Arsenault, M., Nessim, S.J., Halter, J.B., Vranic, M., &
Marliss, E.B. (2000). Epinephrine infusion during moderate intensity exercise
increases glucose production and uptake. American Journal of Physiology –
Endocrinology and Metabolism, 278, E949-E957.
Kreisman, S.H., Halter, J.B., Vranic, M., & Marliss, E.B. (2003). Combined infusion of
epinephrine and norepinephrine during moderate exercise reproduces the
glucoregulatory response of intense exercise. Diabetes, 52, 1347-1354.
Krolewski, A.S., Kosinski, E.J., Warram, J.H., Leland, O.S., Busick, E.J., Asmal, A.C.,
Rand, L.I., Christlieb, A.R., Bradley, R.F., & Kahn, C.R. (1987). Magnitude and
determinants of coronary artery disease in juvenile-onset, insulin-dependent
diabetes mellitus. American Journal of Cardiology, 59, 750-755.
43
Laffel, L. (1999). Ketone bodies: A review of physiology, pathophysiology and
application of monitoring to diabetes. Diabetes Metabolism Research and
Reviews, 15, 412-426.
Lumb, A.N., & Gallen, I.W. (2009). Insulin dose adjustment and exercise in type 1
diabetes: what do we tell the patient? British Journal of Diabetes & Vascular
Disease, 9, 273-277.
Macdonald, M.J. (1987). Postexercise late onset hypoglycaemia in insulin-dependent
diabetic patients. Diabetes Care, 10, 584-588.
Marliss, E.B., Kreisman, S.H., Manzon, A., Halter, J.B., Vranic, M., & Nessim, S.J.
(2000). Gender differences in glucoregulatory responses to intense exercise.
Journal of Applied Physiology, 88, 457-466.
Marliss, E.B., & Vranic, M. (2002). Intense exercise has unique effects on both insulin
release and its roles in glucoregulation. Diabetes, 51, S271-S283.
McMahon, S.K., Ferreira, L.D., Ratnam, N., Davey, R.J., Youngs, L.M., Davis, E.A.,
Fournier, P.A., & Jones, T.W. (2007). Glucose requirements to maintain
euglycaemia after moderate-intensity afternoon exercise in adolescents with type
1 diabetes are increased in a biphasic manner. Journal of Clinical Endocrinology
and Metabolism, 92, 963-968.
Mitchell, T.H., Abraham, G., Schiffrin, A., Leiter, L.A., & Marliss, E.B. (1988).
Hyperglycaemia after intense exercise in IDDM subjects during continuous
subcutaneous insulin infusion. Diabetes Care, 11(4), 311-317.
Møller, N., Jorgensen, J.O.L., Schmitz, O., Møller, J., Christiansen, J.S., Alberti,
K.G.M.M., & Orskov, H. (1990). Effects of a growth hormone pulse on total and
forearm substrate fluxes in humans. American Journal of Physiology.
Endocrinology and Metabolism. 258, E86-E91.
Møller, N., Schmitz, O., Porksen, N., Møller, J., & Jorgensen, J.O.L. (1992). Dose-
response studies on the metabolic effects of a growth hormone pulse in humans.
Metabolism, 41, 172-175.
44
Morgan, W.P. (1985). Affective beneficience of vigorous physical activity. Medicine
and Science in Sports and Exercise, 17(1), 94-100.
Moussa, E., Zouhal, H., Vincent, S., Proiux, J., Delamarche, P., & Gratas-Delamarche,
A. (2003). Effect of sprint duration (6s or 30s) on plasma glucose regulation in
untrained male subjects. Journal of Sports Medicine and Physical Fitness, 43,
546-553.
Myers, S.R., Diamond, M.P., Adkins-Marshall, B.A., Williams, P.E., Stinsen, R., &
Cherrington, A.D. (1991). Effects of small changes in glucagon on glucose
production during a euglycemic, hyperinsulinemic clamp. Metabolism, 40, 66-71.
Nonogaki, K. (2000). New insights into sympathetic regulation of glucose and fat
metabolism. Diabetologia, 43, 533-549.
Opara, E.C., Atwater, I., & Go, V.L. (1988). Characterization and control of pulsatile
secretion of insulin and glucagon. Pancreas, 3, 484-487.
Peirce, N.S. (1999). Diabetes and exercise. British Journal of Sports Medicine, 33, 161-
173.
Porcellati, F., Pampanelli, S., Rossetti, P., Cordoni, C., Marzotti, S., Scionti, L., Bolli,
G.B., & Fanelli, C.G. (2003). Counterregulatory hormone and symptom responses
to insulin-induced hypoglycaemia in the postprandial state in humans. Diabetes,
52, 2774-2783.
Pritzlaff, C.J., Wideman, L., Blumer, J., Jensen, M., Abbott, R.D., Gaesser, G.A.,
Veldhuis, J.D., & Weltman, A. (2000). Catecholamine release, growth hormone
secretion, and energy expenditure during exercise vs. recovery in men. Journal of
Applied Physiology, 89, 937-946.
Purdon, C., Brousson, M., Nyveen, S.L., Miles, P.D.G., Halter, J.B., Vranic, M., and
Marliss, E.B. (1993). The roles of insulin and catecholamines in the
glucoregulatory response during intense exercise and early recovery in insulin-
dependent diabetic and control subjects. Journal of Clinical Endocrinology and
Metabolism, 76, 566-573.
45
Rabasa-Lhoret, R., Bourque, J., Ducros, F., & Chiasson, J-L. (2001). Guidelines for
premeal insulin dose reduction for postprandial exercise of different intensities
and durations in type 1 diabetic subjects treated intensively with a basal-bolus
insulin regimen (Ultralente-lispro). Diabetes Care, 24(4), 625-630.
Raju, B., McGregor, V.P., & Cryer, P.E. (2003). Cortisol elevations comparable to
those that occur during hypoglycemia do not cause hypoglycemia-associated
autonomic failure. Diabetes, 52, 2083-2089.
Rattarsarn, C., Dagogo-Jack, S., Zachwieja, J.J., & Cryer, P.E. (1994). Hypoglycaemia-
induced autonomic failure in IDDM is specific for stimulus of hypoglycaemia and
is not attributable to prior autonomic activation. Diabetes, 43(6), 809-818.
Riddell, M.C., & Bar-Or, O. (2002). Children and adolescents. In N.B. Ruderman, J.T.
Devlin, S. Schneider, et al. (Eds.), Handbook of Exercise in Diabetes (547-566).
Alexandria, VA: American Diabetes Association.
Riddell, M.C., Bar-Or, O., Ayub, B.V., Calvert, R.E., & Heigenhauser, G.J. (1999).
Glucose ingestion matched with total carbohydrate utilization attenuates
hypoglycaemia during exercise in adolescents with IDDM. International Journal
of Sport Nutrition, 9(1), 24-34.
Riddell, M.C., & Perkins, B.A. (2006). Type 1 diabetes and vigorous exercise:
Applications of exercise physiology to patient management. Canadian Journal of
Diabetes, 30(416), 63-71.
Rizza, R.A., Cryer, P.E., & Gerich, J.E. (1979). Role of glucagon, catecholamines, and
growth hormone in human glucose counterregulation. Journal of Clinical
Investigations, 64, 62-71.
Rosen, S.G., Clutter, W.E., Berk, M.A., Shah, S.D., & Cryer, P.E. (1984). Epinephrine
supports the postabsorptive plasma glucose concentration and prevents
hypoglycaemia when glucagon secretion is deficient in man. Journal of Clinical
Investigations, 73, 405-411.
46
Sacks, D.B., Bruns, D.E., Goldstein, D.E., Maclaren, N.K., McDonald, J.M., & Parrott,
M. (2002). Guidelines and recommendations for laboratory analysis in the
diagnosis and management of diabetes mellitus. Clinical Chemistry, 48, 436-472.
Sandoval, D.A., Aftab Guy, D.L., Richardson, M.A., Ertl, A.C., & Davis, S.N. (2004).
Effects of low and moderate antecedent exercise on counterregulatory responses
to subsequent hypoglycaemia in type 1 diabetes. Diabetes, 53, 1798-1806.
Schneider, S.H., Vitug, A., Ananthakrishnan, R., & Khachadurian, A.K. (1991).
Impaired adrenergic response to prolonged exercise in type 1 diabetes.
Metabolism, 40(11), 1219-1225.
Shalitin, S., & Phillip, M. (2008). Hypoglycaemia in type 1 diabetes. Diabetes Care, 31,
S121-S124.
Shemin, D., & Rittenberg, D. (1946). The life span of the human red blood cell. The
Journal of Biological Chemistry, 166, 627-636.
Shilo, S., Sotsky, M., & Shamoon, H. (1990). Islet hormonal regulation of glucose
turnover during exercise in type 1 diabetes. Journal of Clinical Endocrinology
and Metabolism, 70(1), 162-172.
Sigal, R.J., Fisher, S., Halter, J.B., Vranic, M., & Marliss, E.B. (1996). The roles of
catecholamines in glucoregulation in intense exercise as defined by the islet cell
clamp technique. Diabetes, 45(2), 148-156.
Sigal, R.J., Purdon, C., Bilinski, D., Vranic, M., Halter, J.B., & Marliss, E.B. (1994a).
Glucoregulation during and after intense exercise: effects of beta-blockade.
Journal of Clinical Endocrinology and Metabolism, 78, 359-366.
Sigal, R.J., Purdon, C., Fisher, S.J., Halter, J.B., Vranic, M., & Marliss, E.B. (1994b).
Hyperinsulinemia prevents prolonged hyperglycaemia after intense exercise in
insulin-dependent diabetic subjects. Journal of Clinical Endocrinology and
Metabolism, 79(4), 1049-1057.
Simonson, D.C., Koivisto, V., Sherwin, R.S., Ferrannini, E., Hendler, R., Juhlin
Dannfelt, A., & DeFronzo, R.A. (1984). Adrenergic blockade alters glucose
47
kinetics during exercise in insulin-dependent diabetics. Journal of Clinical
Investigation, 73, 1648-1658.
Soedamah-Muthu, S.S., Fuller, J.H., Mulnier, H.E., Raleigh, V.S., Lawrenson, R.A., &
Colhoun, H.M. (2006). High risk of cardiovascular disease in patients with type 1
diabetes in the UK. Diabetes Care, 29, 798-804.
Sonstroem, R.J., & Morgan, W.P. (1989). Exercise and self-esteem: Rationale and
model. Medicine and Science in Sports and Exercise, 21(3), 329-337.
Strawhacker, M.T. (2001). Multidisciplinary teaming to promote effective management
of type 1 diabetes for adolescents. Journal of School Health, 71(6), 213-217.
Temple, M.Y., Bar-Or, O., & Riddell, M.C. (1995). The reliability and repeatability of
the blood glucose response to prolonged exercise in adolescents boys with IDDM.
Diabetes Care, 18(3), 326-332.
The Diabetes Control and Complications Trial Group. (1993). The effect of intensive
treatment of diabetes on the development and progression of long-term
complications in insulin-dependent diabetes mellitus. The New England Journal
of Medicine, 329(14), 977-986.
The Diabetes Control and Complications Trial Research Group. (1995). The effect of
intensive therapy on the development and progression of diabetic nephropathy in
the diabetes control and complications trial. Kidney International, 47, 1703-1720.
Tsalikian, E., Mauras, N., Beck, R.W., Tamborlane, W.V., Janz, K.F., Chase, H.P.,
Wysocki, T., Weinzimer, S.A., Buckingham, B.A., Kollman, C., Xing, D., Ruedy,
K.J. (2005). Impact of exercise on overnight glycemic control in children with
type 1 diabetes mellitus. Journal of Paediatrics, 147, 528-534.
Tuch, B., Dunlop, M., & Proietto, J. (2000). Diabetes research: A guide for
postgraduates. Amsterdam, Netherlands: Harwood Academic Publishers.
Tuominen, J.A., Karonen. S.L., Melamies, L., Bolli, G., & Koivisto, V.A. (1995).
Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting
insulin analogue. Diabetologia, 38, 106-111.
48
Udelsman, R., Goldstein, D.S., Loriaux, D.L., & Chrousos, G.P. (1987).
Catecholamine-glucocorticoid interactions during surgical stress. Journal of
Surgical Research, 43, 539-545.
Unger, R.H., & Orci, L. (1994). Glucagon. In C.R. Kahn & G.C. Weir (Eds.), Joslin’s
Diabetes Mellitus (pp 170). Philadelphia, PA: Lea & Febiger.
Utter, A.C., Kang, J., Nieman, D.C., Williams, F., Robertson, R.J., Henson, D.A.,
Davis, J.M., & Butterworth, D.E. (1999). Effect of carbohydrate ingestion and
hormonal responses on ratings of perceived exertion during prolonged cycling and
running. European Journal of Applied Physiology, 80, 92-99.
Wasserman, D.H., and Zinman, B. (1994). Exercise in individuals with IDDM. Diabetes
Care, 17, 924-937.
White, R.D., & Sherman, C. (1999). Exercise in diabetes management: Maximizing
benefits, controlling risks. The Physician and Sportsmedicine, 27(4), 63-76.
Widom, B., Kinsley, B.T., & Simonson, D. (1991). Women and men differ in
counterregulatory hormone responses to hypoglycaemia (Abstract). Diabetes, 40,
543.
Wolfe, R.R., Nadel, E.R., Shaw, J.H.F., Stephenson, L.A., & Wolfe, M.H. (1986). Role
of changes in insulin and glucagon in glucose homeostasis in exercise. Journal of
Clinical Investigations, 77, 900-907.
Chapter Two
Effect of Antecedent
Moderate‐Intensity Exercise on
the Glycaemia‐Increasing Effect of
a 30‐second Maximal Sprint
50
2.1 Abstract
Recently, the glycaemia-increasing effect of a short sprint has been proposed as a
potential clinical tool for minimizing the risk of exercise-mediated hypoglycaemia in
individuals with type 1 diabetes. However, previous research has shown that an
antecedent bout of moderate-intensity exercise may blunt the counterregulatory
hormone responses to a second bout of moderate-intensity exercise performed several
hours later. Consequently, the purpose of the present study was to investigate whether
an antecedent bout of moderate-intensity exercise also attenuates the counterregulatory
hormone and glycaemia-increasing responses to a maximal 30-second sprint. Eight
healthy young males (age 21.8 1.8 years; BMI 23.9 2.2 kg·m-2; O2peak 48.6 6.6
ml·kg-1·min-1; mean SD) visited the laboratory on two occasions during which they
either rested for 60 minutes (CON) or performed 60 minutes of moderate-intensity
cycling at ~65% O2peak (EX). Following EX or CON, each participant rested for 3
hours and 15 minutes before performing a 30-second maximal cycling sprint. The
response of blood glucose and the counterregulatory hormones was monitored for one
hour of recovery. Mean blood glucose concentrations prior to the 30-second sprint were
similar between trials (4.46 0.20 mM CON; 4.44 0.15 mM EX). In response to the
sprint, blood glucose levels significantly increased, reaching similar maximal levels at
10 minutes of recovery (5.44 0.38 mM CON; 5.43 0.23 mM EX). However, blood
glucose then declined at a faster rate following EX, resulting in significantly lower
blood glucose levels at 45 minutes of recovery compared to CON (4.98 0.15 mM
CON; 4.50 0.10 EX; p = 0.024). The faster fall in blood glucose levels in EX
compared to CON was associated with a more consistent rise in glucose rate of
disappearance (Rd) above the rate of appearance (Ra) during recovery. This might be
explained, at least in part, by the lesser post-exercise rise in growth hormone levels in
EX (p < 0.05). Furthermore, plasma insulin levels were significantly lower at 45
minutes of recovery (p = 0.042) in EX compared to CON. These results suggest that a
prior bout of moderate-intensity exercise does not affect the glycaemia-increasing
response of a 30-second sprint; however, the subsequent decline in blood glucose to
baseline is more rapid. This highlights the need for further investigations in individuals
with type 1 diabetes before sprinting can be safely recommended as a tool for
decreasing the risk of exercise-mediated hypoglycaemia.
51
2.2 Introduction
Individuals with type 1 diabetes mellitus (T1DM) strive to achieve optimal blood
glucose levels by balancing carbohydrate intake with exogenous insulin administration.
Unfortunately, an ideal balance is often hard to achieve because external factors, such as
exercise, make management of blood glucose levels more difficult. Regular exercise has
many well-documented benefits for healthy individuals, as well as those with T1DM,
including lowered risk of cardiovascular disease, obesity, and hypertension, as well as
improved self-esteem and reduced anxiety (Colberg & Swain, 2000; Morgan, 1985;
Sonstroem & Morgan, 1989). Despite these benefits, moderate-intensity exercise causes
a decline in blood glucose levels in individuals with T1DM and consequently carries an
increased risk of hypoglycaemia, both during exercise (Tuominen et al., 1995) and for
up to 31 hours of recovery (Macdonald, 1987; McMahon et al., 2007). This is of great
concern given that an episode of severe hypoglycaemia can lead to convulsions,
unconsciousness, and even death (Bolli, 2003; Chiarelli et al., 1999). As a result of the
increased risk of hypoglycaemia, many individuals with T1DM are advised to be
cautious and continually monitor their blood glucose levels while being physically
active (Choi & Chisholm, 1996).
Current guidelines for individuals with T1DM to avoid hypoglycaemia during exercise
are very general as a result of the wide variety of prescribed insulin regimens, range of
activities pursued, and individual variability in the blood glucose response to exercise
(Colberg, 2000). Furthermore, many guidelines do not acknowledge that different
intensities of exercise produce different glycaemic responses, with not all types of
exercise necessarily increasing the risk of hypoglycaemia (Guelfi et al., 2007). For
example, 10 to 15 minutes of sustained high-intensity exercise has been shown to
stimulate a rise in blood glucose levels both during exercise and recovery, thereby
carrying little to no risk of acute hypoglycaemia for individuals with T1DM (Purdon et
al., 1993; Riddell & Perkins, 2006). Of even greater significance, a bout of high-
intensity cycling at 130% O2max for as little as 78 seconds has been shown to elicit a
marked rise in blood glucose levels in both individuals with and without T1DM, with a
greater and more transient increase in individuals with T1DM (Harmer et al., 2006).
This glycaemic response can be explained, in part, by an increase in the catecholamine
hormones, epinephrine and norepinephrine, which stimulate a large rise in glucose
52
production that far exceeds the rise in glucose uptake (Marliss et al., 2000; Marliss &
Vranic, 2002; Moussa et al., 2003; Purdon et al., 1993).
The glycaemia-increasing effect of high-intensity exercise may provide a promising tool
for minimizing the risk of exercise-induced hypoglycaemia. However, 10 to 15 minutes,
and possibly even 78 seconds, of sustained high-intensity exercise is likely too
strenuous for the majority of the T1DM population to adopt as a regular form of
exercise. For this reason, Bussau and colleagues (2006; 2007) investigated the
glycaemic response to a maximal sprint as short as 10 seconds, performed immediately
before or after 20 minutes of moderate-intensity exercise in individuals with T1DM. It
was found that the inclusion of a sprint did not alter the decline in blood glucose during
exercise; however, it did lead to a stabilization of blood glucose levels during the first
hour of recovery, while levels continued to decline in recovery when no sprint was
performed, thereby decreasing the risk of early post-exercise hypoglycaemia (Bussau et
al., 2006; Bussau et al., 2007). This blood glucose response was attributed to a marked
rise in the catecholamines, growth hormone, and cortisol resulting from the sprint
(Bussau et al., 2006). The risk of hypoglycaemia during and after moderate-intensity
exercise may also be reduced by performing repeated short maximal sprints throughout
continuous moderate-intensity exercise. In a study by Guelfi and colleagues (2005),
individuals with T1DM performed 30 minutes of moderate-intensity exercise either
with or without the addition of 4-second sprints performed every 2 minutes. In
comparison to moderate-intensity exercise alone, blood glucose declined significantly
less during moderate-intensity exercise when the sprints were added. Furthermore, the
addition of sprints caused a stabilization of blood glucose levels during recovery, while
levels continued to decline after moderate-intensity exercise alone (Guelfi et al., 2005).
Although the beneficial effects of sprinting on blood glucose levels may be an
encouraging breakthrough for decreasing the risk of hypoglycaemia during exercise,
factors that may impair the efficacy of a sprint need to be investigated before it can be
safely recommended for individuals with T1DM. For instance, it is well established that
a bout of antecedent moderate-intensity exercise can blunt the counterregulatory
hormone responses to subsequent moderate-intensity exercise performed hours later on
the same day (Galassetti et al., 2001). Whether prior exercise influences the glycaemia-
increasing response of a maximal sprint effort is not known. Since the glycaemia-
increasing effect of a sprint is mediated by an increase in the counterregulatory
hormones, any blunting of the counterregulatory hormone response by antecedent-
53
moderate intensity exercise may reduce the beneficial effects of sprinting on blood
glucose levels. Therefore, the purpose of this study was to investigate the blood glucose
and counterregulatory hormone responses to a 30-second maximal sprint performed
approximately 3 hours after a bout of antecedent moderate-intensity exercise. This issue
was examined in non-diabetic participants to better understand how antecedent exercise
affects the glycaemia-increasing effect of sprinting under non-pathological conditions.
The information thus obtained will form the basis for future research on individuals
with T1DM and hopefully contribute to the publication of more complete exercise
guidelines for this population.
2.3 Research Design and Methods
2.3.1 Participants
Eight healthy, physically active men between the ages of 18 and 25 (See Table 2.1 for
characteristics of participants) were recruited from the local community. Participation in
a minimum of 30 minutes of moderate-intensity activity on 3 days a week was required
to be considered physically active. No participants suffered from any exercise-limiting
musculoskeletal injuries or were taking any form of medication. All participants were
informed of the purpose of the study and any possible risks associated with exercise and
blood sampling. Informed consent was obtained in accordance with the Princess
Margaret Hospital Ethics Committee (Appendix A). Ethics approval was granted by
the Princess Margaret Hospital Ethics Committee and also by The University of
Western Australia Human Research Ethics Committee (Appendix B).
54
Table 2.1. Characteristics of Study Participants (n = 8)
Characteristic Mean ± SD
Age (years) 21.8 ± 1.8
Height (cm) 177.6 ± 7.7
Body Mass (kg) 75.6 ± 10.4
Body Mass Index (kg/m2) 23.9 ± 2.2
O2peak (ml/kg/min) 48.6 ± 6.6
O2peak, peak oxygen consumption
2.3.2 Experimental Design
Each participant was required to attend the Clinical and Metabolic Research Unit at
Princess Margaret Hospital on three occasions, each separated by at least one week. The
first visit was a familiarization session during which the participant was familiarized
with the equipment and procedures to be used, as well as with the research team. Each
participant also completed an incremental exercise test on a cycle ergometer to measure
his peak oxygen consumption ( O2peak) and to determine the exercise workload for
the subsequent experimental trial. The subsequent two visits involved an exercise trial
(EX) and a control rest trial (CON) in order to determine the effect of an antecedent
bout of exercise on the glucose and counterregulatory responses to a maximal sprint
effort. To avoid any order effects, the EX and CON trials were administered in a
randomized counterbalanced design, with each participant acting as his own control. On
one occasion, the participant performed 60 minutes of moderate-intensity exercise (EX)
on a cycle ergometer and then rested for 3 hours and 15 minutes before performing a
30-second maximal sprint. On the other occasion, the participant rested on the bike for
60 minutes (CON) prior to resting for a further 3 hours and 15 minutes before
performing the 30-second maximal sprint.
55
2.3.3 Familiarization Session
The primary goal of the familiarization session was to ensure that each participant was
comfortable with the research team, equipment, and procedures that were to be used
during the subsequent experimental trials. All participants were instructed to avoid
caffeine, alcohol and physical activity in the 24 hours prior to the familiarization
session. Upon arrival to the lab, standing height was measured, without shoes, against a
wall using a measuring tape (SECA, Model 240). Body mass was also measured with
the participant centered on an electronic scale (SECA Alpha, Model 770), with no shoes
and minimal clothing. An incremental exercise test, lasting approximately 20 minutes,
was then performed on a Front Access Cycle Ergometer (Exertech, Repco, Melbourne
Australia) to establish each participant’s peak oxygen consumption ( O2peak). Briefly,
this involved measuring resting oxygen consumption for 3 minutes for familiarization,
followed by initiation of cycling at 50-90 W, depending on the participant’s current
level of physical activity. The intensity of cycling was increased by 40 W every 3
minutes until volitional exhaustion was reached. During exercise, participants breathed
through a calorimetry mask so that the volume of expired gas, as well as the fractions of
oxygen and carbon dioxide in the expired air, could be measured using a computerized
gas analysis system (VMax Spectra, SensorMedics Corporation, USA). These
parameters were used to calculate each participant’s O2peak, which was subsequently
used to determine the appropriate workload (65% O2peak) for the EX trial. Heart rate
(HR) (Polar Heart Rate Monitor) was also measured throughout the exercise test as an
additional indicator of exercise intensity.
2.3.4 Experimental Trials
Three days prior to each experimental trial, each participant came to the Laboratory to
be briefed on the study restrictions and fitted with an accelerometer (Activity Monitor
GT1M, Actigraph, Florida USA) to be worn for the 3 days leading up to the trial. This
was to ensure that no vigorous physical activity was done during the 24 hours prior to
56
the trial as antecedent exercise has been shown to blunt the counterregulatory responses
to subsequent exercise (Galassetti et al., 2001). Participants were also asked to abstain
from caffeine and alcohol in the 24 hours prior to each trial. Finally, participants were
asked to record their food and drink intake (types and amounts) on the day before the
first trial in a self-recorded food diary (Appendix C). The participants were asked to
consume the same food and drink on the day prior to the subsequent trial so that food
intake was standardized between trials.
On the morning of each experimental trial, participants consumed a small liquid
breakfast (Sanitarium Up & Go Liquid Breakfast; 61% carbohydrate, 19% fat, 20%
protein, 16.3 kJ/kg body mass) approximately 40 minutes prior to arrival at the
laboratory following a 10-hour overnight fast. This breakfast was provided to minimize
the risk of hypoglycaemia throughout the trial as a result of the overnight fast. The
amount of carbohydrate in the liquid meal was standardized for each participant based
on body mass (0.6 ± 0.1 g/kg body mass) and matched between trials. Participants were
also required to apply a localized anaesthetic cream (EMLA) and Tegaderm to the left
and right antecubital fossae 1 hour prior to arrival in preparation for cannulation. When
participants arrived in the laboratory at 8:00 am, the localized anesthetic cream (EMLA)
was removed to avoid excessive vasoconstriction as one hour of application was
sufficient for the anesthetic to take effect. The participant then began either cycling on
the Front Access Cycle Ergometer for 60 minutes at 65% O2peak (EX) or resting for
60 minutes while sitting stationary on the cycle ergometer (CON). This exercise
intensity was chosen based on previous research by Galassetti and colleagues (2001)
showing attenuated counterregulatory responses to subsequent exercise after a 90-
minute bout of exercise at 50% O2peak. A reduction in the exercise duration and
increase in intensity was employed to reflect more likely ‘real world’ practices and
current exercise guidelines (American College of Sports Medicine, 1998). Blood lactate
was sampled from the fingertip at 15 and 45 minutes of exercise or the resting control
using a Lactate Pro meter (Arkray Inc., Kyoto, Japan). These lactate samples were used
to ensure that participants were replicating the below anaerobic threshold exercise
conditions used by Galassetti so that the exercise was challenging, but could still be
sustained for a prolonged period of time.
Immediately after this 60-minute period of either exercise or rest, a 20-gauge cannula
(BD InsyteTM) was inserted for blood sampling and kept patent with regular infusion of
0.9% saline. A baseline blood sample was taken at this time to measure the background
57
deuterated glucose enrichment levels. Next, a 22-gauge cannula (BD InsyteTM) was
inserted into the antecubital vein of the contralateral arm for the infusion of the non-
radioactive stable isotope [6,6-2H] glucose using an ASENA Syringe Driver (Alaris
Medical System, Basingstoke, UK). This infusion was commenced 30 minutes after the
cessation of the 60 minutes of exercise or rest with an initial priming bolus of 3 mg.kg-1
body mass, accompanied by a constant infusion of 2.4 mg.kg-1.h-1 for the remainder of
the study. This infusion was necessary for measurement of the rate of appearance (Ra)
and the rate of disappearance (Rd) of glucose to determine whether changes in blood
glucose were a result of glucose production or glucose uptake. Participants were then
required to rest for a further 2 hours and 30 minutes for isotopic equilibrium to be
reached, during which time they watched light movies or read. Water intake was ceased
45 minutes prior to the sprint so that the plasma volume shift in response to the 30-
second sprint could be assessed.
Five minutes prior to the sprint, the participant moved to the cycle ergometer to prepare
for exercise. A 30-second maximal sprint was then performed. Each participant started
the sprint in the standing ready position with their feet strapped into the pedals and their
dominant leg raised at a 45-degree angle, ready to push down. Participants started
sprinting after a three second countdown and were told to cycle as hard as they could
from the start of the sprint, rather than to pace themselves. A high level of verbal
encouragement was provided to maximize the motivation and sprint effort of the
participant. A 30-second sprint was used because the glycaemia-increasing effect of
sprinting is more pronounced after a 30-second sprint compared to a 10-second sprint
(Moussa et al., 2003).
Following the sprint, each participant dismounted the bike and was required to rest for 1
hour in the Laboratory so that the response of glucose kinetics and counterregulatory
hormones to the sprint could be measured. Venous blood samples (23 ml) were taken 15
and 5 minutes before the sprint, as well as at 0, 5, 10, 15, 30, 45, and 60 minutes of
recovery. Prior to each sample, the participant’s hand was warmed in a hot box (Omega
CN 370, Sydney, Australia) at 55-60˚C so that arterialized-venous blood could be
obtained. This is important given that blood glucose concentration varies between the
arteries and veins, and the composition of arterialized venous blood is more indicative
of arterial blood (Liu et al., 1992).
58
Expired air was also collected at periods throughout the study, with each collection
lasting ten minutes. This required participants to breathe into a calorimetry mask, with
their expired gases analyzed by the same Vmax Spectra respiratory analysis system
(SensorMedics Corporation, USA) used during the maximal exercise test. Two gas
samples were taken during the 60 minutes of antecedent exercise or rest, collecting from
15-25 minutes and 40-50 minutes. These gas samples were used to confirm whether the
prescribed exercise workload was accurate (65% O2peak) and any necessary
adjustments to the workload were made accordingly.
After the 1-hour recovery period, the cannulas were removed and the participants were
given a meal before leaving the laboratory. Participants were asked to return to the
Laboratory at least 1 week later to have the accelerometer re-fitted and worn for the
three days prior to their next trial. Three days later, the participant returned to the
Laboratory to complete the alternative trial.
2.3.5 Measurement of Blood Metabolites and Hormones
A number of blood samples were collected throughout the experimental protocol to
measure the blood glucose and counterregulatory response to exercise. Blood glucose
and lactate levels were determined using a YSI Analyzer (YSI Life Sciences, Yellow
Springs, Ohio, USA). The remaining blood was aliquotted to appropriate collection
tubes prior to centrifugation at 4ºC at 3500 rpm (Eppendorf Centrifuge 5810 R,
Hamburg, Germany), with the resultant serum or plasma collected and stored at -40ºC
(with the exception of the deuterated glucose and catecholamines which were stored at
-80ºC). Insulin was assayed from plasma in a lithium heparin tube by non-competitive
chemiluminescent immunoassay (Abbott Architect i2000, Illinois USA). Plasma was
collected for the assay of pancreatic-specific glucagon in a K-EDTA tube with a
Benzamidine HCL additive, and subsequently assayed using a non-competitive radio-
immunoassay (Siemens Medical Solutions Diagnostics Ltd, California, USA). Growth
hormone was assayed from serum collected in a serum clot activator tube by a non-
competitive enzyme immunoassay with a chemiluminescent substrate (Siemens
Immulite 2000 XPi; Siemens Medical Solutions Diagnostics Ltd, California, USA).
Serum was also collected for the assay of cortisol in a serum clot activator tube before
being subsequently assayed using a competitive chemiluminescent immunoassay
59
(Abbott Architect i2000, Illinois USA). Epinephrine and norepinephrine were collected
in a lithium heparin tube with a sodium metabisulfite additive before being extracted on
alumina and eluted with acetic acid. The extracted catecholamines were separated on a
reverse phase column (Ultrasphere; Beckman Coulter, Albany North Shore City, New
Zealand) using a Shidmadzu HPLC system (Shidmadzu Scientific Instruments,
Australia) with an ESA Coulochem-II Electrochemical Detector (California, USA).
Additionally, haemoglobin levels were measured using a Hemocue analyzer (HemoCue
Hb 201+, Ängelholm, Sweden), while haematocrit was measured using a
microhaematocrit reader (Clements) after centrifuging for 4 minutes (H.I. Clements Pty
Ltd. Sydney, Australia). Measurements of haemoglobin and haematocrit were used to
determine any plasma volume changes resulting from the sprint, using the methods of
Dill and Costill (1974). In addition, blood pH was measured using an ABLTM 725 Blood
Gas Analysis System (Radiometer, Copenhagen).
2.3.6 Measurement of [6,6-2H] glucose enrichment, and glucose Ra and Rd calculations
The level of plasma enrichment of [6,6-2H] glucose was determined from plasma
collected in a standard lithium heparin tube using gas chromatography mass
spectrometry (GCMS; Agilent Selective Detector, Agilent technologies, Ryde, NSW,
Australia). This method, as previously described by Hannestad and Lundblad (1997),
involved the conversion of [6,6-2H] glucose to its aldonitrile derivative, which was
subsequently measured using GCMS. Glucose Ra and Rd were then calculated using the
one-compartment fixed-volume non-steady state model of Steele (Wolfe & Chinkes,
2005). This model assumes that the [6,6-2H] glucose distribution volume is stable, and
that changes in plasma glucose concentration only result from changes in glucose Ra
and Rd. However, these assumptions may not be valid during a maximal sprint effort.
This is because it has been repeatedly shown that performance of exercise, particularly
at a high-intensity, is associated with a marked fluid shift out of the vasculature and into
the active muscles (Raja et al., 2006; Ward et al., 1996; Watson et al., 1993; Sjøgaard et
al., 1985; Sjøgaard & Saltin, 1982). This is due in part to the large increase in the levels
of lactate, hydrogen ions, and inorganic phosphates within the muscle cell which creates
a large osmotic gradient that causes a marked shift of fluid out of the vasculature and
into the active muscles (Raja et al., 2006; Ward et al., 1996; Watson et al., 1993,
60
Sjøgaard et al., 1985, Sjøgaard & Saltin, 1982). Therefore, some of the change in
plasma glucose concentration may be attributed to a shift in plasma volume, rather than
to a change in glucose Ra and Rd. Consequently, glucose Ra and Rd were re-calculated
after correcting for any changes in plasma glucose concentration that could be explained
by a shift in plasma volume, assuming that any relative change in plasma volume
reflects a change in the [6,6-2H] glucose distribution volume.
2.3.7 Statistical Analyses
The data from this study were analyzed for changes over time and between treatments
using SPSS 17.0 Software for Windows. Two-way (time x trial) Repeated-Measures
Analysis of Variance was used to determine whether differences existed, followed by
post-hoc pairwise comparisons to determine where the differences lay. Area under the
curve (AUC) was calculated using the trapezoidal rule, with one-way repeated-measures
ANOVA used to compare between trials. In addition, a Pearson correlation was
undertaken between relative mean power output in the 30-second sprint and the
maximum change in blood glucose, as well as AUC for blood glucose. Statistical
significance was accepted at the p < 0.05 level. With the exception of tables (mean ±
SD), all data are expressed as mean ± SEM.
2.4 Results
2.4.1 Characteristics of the 60-minute antecedent bout of exercise and maximal sprint efforts
During the EX trial, participants worked at 65 ± 6% of their O2peak during the 60
minutes of antecedent exercise, compared to the equivalent rest period in which oxygen
consumption remained at basal levels (Table 2.2). Blood lactate remained at a low level
throughout the 60 minutes of exercise (p > 0.05 compared to control). Furthermore, the
61
antecedent bout of exercise was accompanied by a significant rise in heart rate when
compared to antecedent rest (p < 0.05; Table 2.2). With respect to the number of steps
taken in the 3 days preceding each trial as determined from accelerometry, there was no
significant difference between trials in the total number of steps taken over the entire 3
day period (19,385 ± 3,176 steps CON; 22,540 ± 1,663 steps EX; p = 0.397), or when
the day preceding each trial was considered in isolation (4,980 ± 2,632 steps CON;
6,268 ± 825 steps EX; p = 0.327), suggesting antecedent activity levels were matched
between trials.
Participants displayed no significant difference between trials in the absolute or relative
mean power output during the 30-second sprint performed after 60 minutes of
antecedent exercise or rest (Table 2.3). There was also no significant difference in the
absolute or relative peak power output during the 30-second sprint between trials.
Table 2.2. Response of oxygen consumption, blood lactate, and heart rate to
60 minutes of antecedent exercise or rest (control)
Variable Exercise Control
Mean O2 (ml·kg·min-1) 30.5 ± 3.6* 4.8 ± 0.7
Mean % O2peak 65 ± 6* 9 ± 7
Blood lactate (mM)
at 15 minutes 4.5 ± 1.7 3.4 ± 2.3
Blood lactate (mM)
at 45 minutes 3.5 ± 1.7 2.2 ± 1.0
Mean heart rate (bpm) 143 ± 10* 78 ± 6
Data are means ± SD. O2, oxygen consumption. % O2peak, percentage of peak oxygen consumption. *Statistically significant difference (p < 0.05) vs. control.
62
Table 2.3 Comparison of mean and peak power output during a 30-second maximal
sprint following 60 minutes of antecedent exercise or rest (control)
Variable Exercise Control
Absolute (W) Relative (W/kg) Absolute (W) Relative (W/kg)
Mean Power
815 ± 180 10.9 ± 1.4 818 ± 170 10.7 ± 1.3
Peak Power
1,359 ± 336 18.2 ± 3.1 1,335 ± 316 17.9 ± 2.6
Data are means ± SD. No significant differences between trials (p > 0.05).
2.4.2 Blood glucose response to a 30-second maximal sprint
Prior to the 30-second maximal sprint, baseline blood glucose concentrations were 4.46
± 0.07 mM and 4.44 ± 0.05 mM in CON and EX, respectively (p = 0.724; Fig 2.1). In
response to the 30-second maximal sprint, blood glucose levels increased significantly
and similarly in both trials, reaching a peak at 10 minutes of recovery (5.44 ± 0.13 mM
and 5.43 ± 0.08 mM in CON and EX, respectively; p = 0.86). After this time, blood
glucose levels began to steadily decline, returning to baseline in EX by 45 minutes of
recovery (p = 0.619) and in CON by 60 minutes of recovery (p = 0.147). The more
rapid decline in blood glucose levels following EX resulted in significantly lower blood
glucose levels at 45 minutes of recovery compared to CON (4.98 ± 0.15 CON; 4.50 ±
0.10 EX; p = 0.024), and a tendency for lower blood glucose levels following EX at 30
(p = 0.067) and 60 (p = 0.072) minutes of recovery. Accordingly, the AUC for blood
glucose approached significance (p = 0.057), with a tendency for lower levels following
EX.
63
There were no relationships between relative mean power output in the 30-second sprint
and the maximum change in blood glucose (r = 0.55, p = 0.157) and between relative
power output and the AUC for glucose (r = 0.40, p = 0.327).
Figure 2.1 Blood glucose response to a 30-second maximal sprint (represented by
vertical bar) performed after 60 minutes of antecedent exercise (EX) or rest (CON). All
data are means ± SEM. aStatistically significant difference (p < 0.05) from baseline
(time -5 minutes). bStatistically significant difference (p < 0.05) between CON and EX.
2.4.3 Glucose rate of appearance and rate of disappearance determined without corrections in plasma volume
Immediately following the 30-second maximal sprint, Ra remained at baseline levels in
both trials (Fig 2.2a; Fig 2.2b). This was followed by a significant increase in Ra above
baseline at 5 minutes post-sprint in both CON (p = 0.044) and EX (p < 0.001), before
returning to baseline levels at 10 minutes post-sprint where Ra remained for the duration
of recovery. In contrast, Rd declined immediately following the 30-second sprint in both
trials, dropping significantly below baseline levels in CON at 0 minutes of recovery
(p = 0.009). After this initial decline, Rd quickly returned to baseline, where it remained
for the rest of recovery in CON, while for EX levels increased significantly above
64
baseline at 5 (p = 0.006) and 45 minutes of recovery (p = 0.013). There was no
significant difference in Ra or Rd between trials (p > 0.05).
Within each trial, Ra rose significantly above Rd immediately following the 30-second
sprint. Ra was significantly greater than Rd at 0 (p < 0.001) and 10 (p = 0.010) minutes
of recovery following CON and 0 (p < 0.001) and 5 (p = 0.002) minutes of recovery
following EX. Following this, Ra was matched by Rd until 15 and 45 minutes of
recovery in EX and CON, respectively. At 15 minutes of recovery following EX, Rd
rose significantly above Ra for the next 45 minutes of recovery (p = 0.044, p = 0.010,
and p < 0.001 at 15, 30, and 45 minutes, respectively). Rd also increased above Ra
following CON, but not until 45 (p < 0.001) and 60 (p = 0.004) minutes of recovery.
2.4.4 Glucose rate of appearance and rate of disappearance when corrected for plasma volume changes
The 30-second maximal sprint caused a significant shift in plasma volume and
associated increase in haematocrit (Figure 2.3; Table 2.4). Immediately following the
sprint, the change in plasma volume decreased significantly below 0 in both the CON
(p < 0.001) and EX trials (p < 0.001). After this initial shift, plasma volume began to
return towards baseline levels through the accumulation of several small changes in
plasma volume throughout the remainder of recovery. There was no significant
difference in the shift in plasma volume between trials, with the exception of between
45 and 60 minutes of recovery where a significantly greater shift was observed
following EX (p = 0.033). The 30-second maximal sprint also resulted in a significant
increase in haematocrit above pre-sprint levels, followed by a return to pre-sprint levels
at 30 minutes of recovery before declining below baseline levels in both trials. There
was no significant difference in the haematocrit response between trials (p > 0.05).
After correcting Ra and Rd for these changes in plasma volume, there was still no
difference in glucose Ra or Rd between trials (p > 0.05; Fig 2.4a; Fig 2.4b). The plasma
volume shift did not affect the pattern of Ra response compared to that which was
previously described when no correction for plasma volume was made, with a
significant increase above baseline at 5 minutes of recovery in both trials (p = 0.045 in
CON; p < 0.001 in EX). In comparison, glucose Rd was highly influenced by the shift in
65
plasma volume. During CON, Rd did not decline at the onset of recovery, with no
significant difference from baseline seen at any time point after the application of a
plasma volume correction. Similarly, the significant difference from baseline Rd seen at
45 minutes of recovery in EX was not present after the correction.
When the glucose Ra and Rd were compared within trials using the values corrected for
plasma volume changes, Ra and Rd were no longer significantly different immediately
after the sprint in both trials. Ra was significantly higher than Rd in CON at 5 and 10
minutes of recovery, while Rd exceeded Ra at 60 minutes of recovery. Similarly, Ra
exceeded Rd at 5 and 10 minutes of recovery following EX, but Rd exceeded Ra earlier
in recovery (at 45 minutes) compared to CON.
2.4.5 Plasma insulin response to a 30-second maximal sprint
Plasma insulin levels were similar in both trials prior to the 30-second sprint (Fig 2.5).
Immediately after sprinting, plasma insulin levels were significantly lower in EX
compared to CON (p = 0.006). Plasma insulin levels then began to rise in both trials,
reaching similar peak levels at 30 minutes of recovery (10.19 ± 1.91 and 8.11 ± 1.06
µU/ml in CON and EX, respectively, p = 0.281). Insulin levels returned to baseline at
45 minutes of recovery in EX, but still remained significantly elevated above basal
levels at 60 minutes of recovery in CON. Insulin levels were significantly higher at 45
minutes of recovery in CON compared to EX (p = 0.042).
2.4.6 Counterregulatory hormone response to a 30-second maximal sprint
Plasma glucagon levels were similar in both trials prior to the 30-second sprint
(p = 0.349; Fig 2.6). Immediately following the sprint, plasma glucagon levels increased
significantly and similarly above baseline in both trials (p = 0.016 and p = 0.007 in
CON and EX, respectively), returning to baseline by 15 minutes of recovery. Plasma
glucagon levels then increased significantly above baseline in EX again at 60 minutes of
recovery, resulting in a significant difference between CON and EX at this time
(p = 0.015).
66
Plasma epinephrine was similar in both trials prior to the 30-second sprint (p = 0.387;
Fig 2.7a). Plasma epinephrine levels then increased significantly above baseline in
response to the sprint, peaking immediately post-sprint (0 minutes of recovery) before
beginning to return to baseline. A significant difference in epinephrine levels existed
between trials at 15 minutes of recovery, although this difference was minimal with
slightly higher epinephrine following EX compared to CON (p = 0.036). Plasma
norepinephrine was similar in both trials prior to the sprint (p = 0.472; Fig 2.7b).
Immediately following the sprint, plasma norepinephrine levels increased significantly
and similarly above baseline in both trials (p = 0.001 and p = 0.002 in CON and EX,
respectively). Plasma norepinephrine levels then began to decline towards baseline for
the remainder of recovery. There was no significant difference in norepinephrine levels
between trials.
Plasma growth hormone levels were similar in both trials prior to the 30-second sprint
(0.963 ± 0.287 mIu/L and 3.507 ± 3.244 mIu/L in CON and EX, respectively;
p = 0.431; Fig 2.8). Immediately after the sprint, growth hormone levels began to rise,
reaching peak levels at 30 minutes of recovery. This growth hormone response was
significantly blunted by the performance of antecedent moderate exercise, with
significantly lower growth hormone levels at 15, 30, and 45 minutes of recovery in EX
compared to CON (p = 0.048, p = 0.025, p = 0.028 at 15, 30, and 45 minutes of
recovery, respectively).
Plasma cortisol levels were also similar in both trials prior to the 30-second sprint (265
± 22 nmol/L and 238 ± 20 nmol/L in CON and EX, respectively; Fig 2.9). In response
to the sprint, plasma cortisol levels increased significantly and similarly above baseline
in both trials, reaching maximal levels at 30 minutes of recovery (p = 0.524). There was
no significant difference in plasma cortisol levels between trials at any point of
recovery.
67
Figure 2.2a Glucose Ra and Rd in response to a 30-second maximal sprint (represented
by vertical bar) performed after 60 minutes of rest (CON). All data are means ± SEM. aStatistically significant difference (p < 0.05) from baseline (time -5 minutes). bStatistically significant difference (p < 0.05) between Ra and Rd.
Figure 2.2b Glucose Ra and Rd in response to a 30-second maximal sprint (represented
by vertical bar) performed after 60 minutes of antecedent exercise (EX). All data are
means ± SEM. aStatistically significant difference (p < 0.05) from baseline (time -5
minutes). bStatistically significant difference (p < 0.05) between Ra and Rd.
68
Table 2.4 Percent change in plasma volume (%∆PV) in response to a 30-second
maximal sprint
Time (min) in
relation to sprint
-5 - 0 0 - 5 5 - 10 10 - 15 15- 30 30 - 45 45- 60
Control -10.3 ± 3.3a 0.9 ± 2.7 3.2 ± 2.0
a 2.6 ± 2.3
a 4.9 ± 3.9
a 6.3 ± 3.6
a 0.3 ± 2.4
Exercise -13.3 ± 3.4a 1.0 ± 4.8 3.2 ± 1.5
a 1.7 ± 2.2 8.1 ± 3.8
a 5.5 ± 2.3
a 2.8 ± 2.0
a,b
Data are means ± SD. The 30-second sprint occurred immediately before time 0. Reported %∆PV is
the change over the specified interval. aStatistically significant difference (p < 0.05) from 0. bStatistically significant difference (p < 0.05) between CON and EX.
Figure 2.3 Changes in haematocrit in response to a 30-second maximal sprint
(represented by vertical bar) performed after 60 minutes of antecedent exercise (EX) or
rest (CON). All data are means ± SEM. aStatistically significant difference (p < 0.05)
from baseline (time -5 minutes).
69
Figure 2.4a Glucose Ra and Rd in response to a 30-second maximal sprint
(represented by vertical bar) performed after 60 minutes of rest (CON) when
corrected for plasma volume changes. All data are means ± SEM. aStatistically
significant difference (p < 0.05) from baseline (time -5 minutes). bStatistically
significant difference (p < 0.05) between Ra and Rd.
Figure 2.4b Glucose Ra and Rd in response to a 30-second maximal sprint
(represented by vertical bar) performed after 60 minutes of antecedent exercise
(EX) when corrected for plasma volume changes. All data are means ± SEM. aStatistically significant difference (p < 0.05) from baseline (time -5 minutes). bStatistically significant difference (p < 0.05) between Ra and Rd.
70
Figure 2.5 Plasma insulin response to a 30-second maximal sprint (represented by
vertical bar) performed after 60 minutes of antecedent exercise (EX) or rest (CON). All
data are means ± SEM. aStatistically significant difference (p < 0.05) from baseline
(time -5 minutes). bStatisticallysignificantdifference (p<0.05)betweenCONand
EX.
Figure 2.6 Plasma glucagon response to a 30-second maximal sprint (represented by
vertical bar) performed after 60 minutes of antecedent exercise (EX) or rest (CON). All
data are means ± SEM. aStatistically significant difference (p < 0.05) from baseline
(time -5 minutes). bStatistically significant difference (p < 0.05) between CON and EX.
71
Figure 2.7a Plasma epinephrine response to a 30-second maximal sprint (represented
by vertical bar) performed after 60 minutes of antecedent exercise (EX) or rest (CON).
All data are means ± SEM. aStatistically significant difference (p < 0.05) from baseline
(time -5 minutes). bStatistically significant difference (p < 0.05) between CON and EX.
Figure 2.7b Plasma norepinephrine response to a 30-second maximal sprint
(represented by vertical bar) performed after 60 minutes of antecedent exercise (EX) or
rest (CON). All data are means ± SEM. aStatistically significant difference (p < 0.05)
from baseline (time -5 minutes).
72
Figure 2.8 Plasma growth hormone response to a 30-second maximal sprint
(represented by vertical bar) performed after 60 minutes of antecedent exercise (EX) or
rest (CON). All data are means ± SEM. aStatistically significant difference (p < 0.05)
from baseline (time -5 minutes). bStatistically significant difference (p < 0.05) between
CON and EX.
Figure 2.9 Plasma cortisol response to a 30-second maximal sprint (represented by
vertical bar) performed after 60 minutes of antecedent exercise (EX) or rest (CON). All
data are means ± SEM. aStatistically significant difference (p < 0.05) from baseline
(time -5 minutes).
73
2.4.7 Blood lactate, blood pH, and heart rate responses to a 30-second maximal sprint
Mean blood lactate levels at baseline prior to the 30-second sprint were 0.59 ± 0.06 mM
and 0.52 ± 0.03 mM in CON and EX, respectively (p = 0.097; Fig 2.10). In response to
the 30-second maximal sprint, blood lactate increased significantly above baseline in
both trials, reaching similar peak levels of 9.59 ± 0.67 mM and 9.33 ± 0.64 mM in CON
and EX, respectively, at 5 minutes of recovery (p = 0.505). Blood lactate levels then fell
progressively, but still remained above basal levels at 60 minutes of recovery (p < 0.05
in both CON and EX), with no significant differences between trials at any point. Mean
blood pH prior to the sprint was similar in both groups (7.36 ± 0.01 in CON; 7.38 ±
0.01 in EX; p = 0.098; Fig 2.11). Performance of the 30-second maximal sprint caused a
significant decline in blood pH in both groups, with a minimum pH of 7.08 ± 0.02 and
7.07 ± 0.01 reached in EX and CON, respectively, at 5 minutes of recovery. Afterwards,
pH increased, progressively returning to baseline in both groups at 45 minutes of
recovery. A significant difference in pH was noted between trials at 45 minutes of
recovery (p = 0.020), with EX displaying a significantly higher pH. Finally, the sprint
was associated with a significant rise in heart rate, which peaked immediately post-
sprint (150 ± 7 bpm CON; 156 ± 5 bpm EX) and returned to baseline levels by 5
minutes of recovery.
74
Figure 2.10 Blood lactate response to a 30-second maximal sprint (represented by
vertical bar) performed after 60 minutes of antecedent exercise (EX) or rest (CON). All
data are means ± SEM. aStatistically significant difference (p < 0.05) from baseline
(time -5 minutes).
Figure 2.11 Blood pH response to a 30-second maximal sprint (represented by vertical
bar) performed after 60 minutes of antecedent exercise (EX) or rest (CON). All data are
means ± SEM. aStatistically significant difference (p < 0.05) from baseline (time -5
minutes). bStatistically significant difference (p < 0.05) between CON and EX.
75
2.5 Discussion
Recently, it has been reported that the performance of one or several short maximal
sprints before, during, or after moderate-intensity exercise attenuates the decline in
blood glucose levels during recovery in individuals with T1DM (Bussau et al., 2006;
Bussau et al., 2007; Guelfi, et al., 2005). This has been attributed, in part, to the
glucose-increasing effect of high-intensity exercise (Harmer et al., 2006; Marliss &
Vranic, 2002; Moussa et al., 2003; Purdon et al., 1993). Although these findings suggest
that sprinting may be a useful tool for decreasing the risk of exercise-mediated
hypoglycaemia, factors that may impair its efficacy must be identified before this type
of exercise can be safely recommended to individuals with T1DM. Of interest,
Galassetti and colleagues (2001) found that a 90-minute bout of antecedent moderate-
intensity exercise blunted the counterregulatory hormone responses to an identical bout
of exercise performed 3 hours later. This raises the question of whether antecedent
exercise may also impair the glycaemia-increasing effect of sprinting performed hours
later. The present study shows that 60 minutes of moderate-intensity exercise does not
affect the rise in blood glucose levels associated with a 30-second maximal sprint
performed approximately 3 hours later, with a similar increase in blood glucose levels
observed in both EX and CON trials. However, as recovery progresses, the decline in
blood glucose levels is more rapid when the sprint follows a bout of moderate-intensity
exercise. These results raise the possibility that antecedent moderate-intensity exercise
might also have the potential to reduce the efficacy of sprinting in decreasing the risk of
exercise-mediated hypoglycaemia in individuals with T1DM.
Although the transient glycaemia-increasing effect of sprinting seen in our study is
supported by the findings of others in non-diabetic individuals, this is the first study to
show that antecedent exercise increases the rate of fall in blood glucose after it reaches
peak levels. Previous research has shown that a 30-second maximal sprint results in a
comparable transient rise in blood glucose levels to that seen here, with blood glucose
levels returning to pre-exercise levels within one hour of recovery (Moussa et al., 2003).
Conversely, 10 to 15 minutes of intense aerobic exercise (>80% O2max) has been
shown to produce a greater rise in blood glucose levels than a 30-second maximal sprint
(Marliss & Vranic, 2002). However, this study shows for the first time that the decline
in blood glucose levels is more rapid after a sprint if preceded by a one-hour bout of
moderate intensity exercise performed several hours earlier.
76
An initial examination of our findings suggests that, when changes in plasma volume
are not taken into consideration, the increase in blood glucose levels at the onset of
recovery in both trials results mainly from a transient fall in glucose Rd, since sprinting
appears to have no immediate effect on glucose Ra. However, over the following 5-10
minutes of recovery, there is a further rise in blood glucose levels despite the marked
increase in glucose Rd in both trials. This increase in blood glucose level is the result of
the concomitant rise in glucose Ra that significantly exceeds the rise in glucose Rd. It is
noteworthy, however, that this pattern of change in glucose Ra differs markedly from
that associated with high-intensity aerobic exercise, where glucose Ra has been shown
to be already near maximal at the onset of recovery (Kreisman et al., 2000; Marliss et
al., 2000; Marliss & Vranic, 2002; Mitchell et al., 1988; Purdon et al., 1993; Sigal et al.,
1994). Another noteworthy difference is the transient fall in glucose Rd at the onset of
recovery, compared to the reported high glucose Rd immediately after high-intensity
aerobic exercise (Kreisman et al., 2000; Marliss et al., 2000; Marliss & Vranic, 2002;
Purdon et al., 1993; Sigal et al., 1994). These differences may be due to the varied
nature of high-intensity aerobic exercise as compared to the physiological requirements
of a short maximal anaerobic sprint. Regardless, the mechanisms underlying the decline
in glucose Rd remain to be determined, it is possible that the intramuscular accumulation
of glucose 6-phosphate that typically occurs with intense exercise may inhibit the rate of
glucose uptake via a glucose 6-phosphate-mediated inhibition of hexokinase, a key
glycolytic enzyme (Gollnick et al., 1981).
It is important to stress, however, that when the marked changes in plasma volume in
response to the sprint are taken into account, the onset of recovery is no longer
accompanied by a marked decline in glucose Rd. Instead, sprinting appears to have no
immediate effect on glucose Rd. This glucose Rd response still differs from that in non-
diabetic individuals subjected to high-intensity aerobic exercise who display a marked
increase in glucose Rd at the onset of recovery (Kreisman et al., 2000; Marliss et al.,
2000; Marliss & Vranic, 2002; Purdon et al., 1993; Sigal et al., 1994). Again, it is
possible that the absence of any rise in glucose Rd in response to the sprint can be
explained by an inhibition of glucose uptake by elevated glucose 6-phosphate levels.
Furthermore, the lack of a significant difference between glucose Ra and Rd at the onset
of recovery in both trials indicates that the change in plasma volume in response to the
sprint may be high enough to completely account for the early rise in blood glucose
level, with the apparent decline in glucose Rd described above (prior to correction for
77
plasma volume shifts) likely an artifactual result of the fluid shift into the musculature.
However, the continued increase in blood glucose beyond the start of recovery in both
trials cannot be fully explained by the shift in plasma volume. Rather, the rise in
glycaemia at this time likely results, to some extent, from glucose Ra significantly
exceeding glucose Rd. Clearly, our findings show that the well-documented plasma
volume shift associated with intense exercise (Raja et al., 2006; Ward et al., 1996;
Watson et al., 1993, Sjøgaard et al., 1985, Sjøgaard & Saltin, 1982) must be considered
when examining the effect of sprinting on blood glucose levels, as this variable has the
potential to considerably influence the interpretation of glucose kinetics.
The early rise in the levels of the plasma catecholamines immediately after sprinting
suggests that these hormones might play some role in mediating the increase in
glycaemia seen 5 to 10 minutes following the sprint. Others have also reported that the
rise in blood glucose levels associated with sprinting and high-intensity exercise is
accompanied by an immediate increase in plasma epinephrine and norepinephrine levels
(Kreisman et al., 2000; Kreisman et al., 2003; Marliss et al., 2000; Sigal et al., 1994).
There is substantial evidence that such an increase in plasma catecholamine levels
contributes to the rise in blood glucose levels via stimulation of glucose Ra (Kjaer,
1992; Kreisman et al., 2003; Purdon et al., 1993). In this respect, epinephrine and
norepinephrine have been proposed to exert their effects mainly by increasing the rate
of hepatic glucose production (Cryer et al., 2003; Goldstein et al., 1995; Lumb &
Gallen, 2009; Marliss et al., 2000; Rizza et al., 1979; Sigal et al., 1994). Of note, the
absence of any clinically meaningful effect of antecedent moderate-intensity exercise on
the catecholamine response to a sprint does not support our prediction based on the
work of Galassetti and colleagues (2001), which showed that a bout of antecedent
moderate-intensity exercise blunts the epinephrine and norepinephrine responses to a
second bout of moderate-intensity exercise performed several hours later. It is possible
that this discrepancy is the result of an all-out sprint being a much greater stimulus than
moderate-intensity exercise, ultimately overriding any suppression caused by an
antecedent bout of exercise.
Later in recovery, the more rapid decline in blood glucose levels in EX compared to
CON is likely the result of glucose Rd exceeding glucose Ra earlier in recovery in EX.
Indeed, glucose Rd is significantly higher than glucose Ra from 15 to 45 minutes of
recovery in EX, while glucose Rd in CON does not exceed glucose Ra until 45 minutes
of recovery. However, when both glucose Ra and Rd are corrected for changes in plasma
78
volume, glucose Rd rises above glucose Ra much later during recovery in both trials, but
still earlier in EX (45 minutes of recovery) compared to CON (60 minutes of recovery).
Despite the close matching of glucose Ra and Rd until late in recovery, blood glucose
levels begin to decline at 15 minutes of recovery, suggesting that the increasing plasma
volume back towards baseline levels occurring at this time may be responsible for at
least part of the decline in blood glucose concentration. However, the plasma volume
shift cannot account for the faster rate of decline in blood glucose following EX
compared to CON, since the changes in plasma volume were similar between trials until
60 minutes of recovery. Instead, the more rapid decline in blood glucose in EX is most
likely to involve the earlier increment in Rd above Ra as described. Unfortunately, the
analysis described here does not allow us to determine the extent to which changes in
plasma volume must be considered in glucose kinetic analyses, particularly when
working with low rates of changes in plasma volume.
The more rapid fall in blood glucose levels in EX compared to CON is unlikely to be
associated with the levels of the plasma catecholamines, since the levels of these
hormones were similar between trials, except for a small difference in epinephrine at 15
minutes of recovery that would be unlikely to have any clinically meaningful effect on
blood glucose later in recovery. Furthermore, although the level of circulating plasma
insulin is a key mediator of the decline in blood glucose during recovery from high-
intensity exercise (Lumb & Gallen, 2009; Purdon et al., 1993; Riddell & Perkins, 2006;
Sigal et al., 1994), it is noteworthy that the more rapid decline in blood glucose levels in
EX compared to CON was associated with significantly lower plasma insulin levels in
EX at 45 minutes of recovery. The similar glucose Rd in both trials despite lower
plasma insulin levels in EX is consistent with greater insulin sensitivity in EX. Since the
level of muscle glycogen is an important determinant of insulin sensitivity (Derave et
al., 2000), the hypothesized increase in insulin sensitivity in EX may be a result of
lower post-sprint muscle glycogen levels due to the expected cumulative effect of
antecedent exercise and sprinting on muscle glycogen stores.
The more rapid decline in blood glucose levels in EX compared to CON might also be
explained by the attenuated increase in growth hormone levels in EX compared to
CON. Since a sudden increase in growth hormone levels can acutely inhibit glucose
uptake in non-diabetic individuals (Møller et al., 1990; Møller et al., 1992), the
attenuated rise in growth hormone levels in EX might explain the earlier rise of glucose
Rd above glucose Ra in EX compared to CON, thus explaining the more rapid decline in
79
blood glucose levels in EX. Of note, this is the first study to show that the growth
hormone response to a maximal sprint effort is attenuated by a bout of prior moderate-
intensity exercise. This finding is consistent with the work of Galassetti and colleagues
(2001), which demonstrated an attenuated growth hormone response to a bout of
moderate-intensity exercise performed hours after an identical bout of exercise. In
contrast, antecedent moderate-intensity exercise had no effect on the response of
cortisol to sprinting in the present study, a finding which differs from that of Galassetti
and colleagues (2001) who reported an attenuated increase in plasma cortisol levels
during a bout of moderate-intensity exercise following a prior bout of moderate-
intensity exercise. On the other hand, it is unlikely that glucagon contributed to the
more rapid decline in blood glucose in EX compared to CON, given the similar and
transient increase in both trials. With respect to the significant rise in plasma glucagon
levels in EX compared to CON at 60 minutes of recovery, this is likely an antagonistic
response to the rapidly falling blood glucose levels following EX. Since it is the
decrease in the beta cell secretion of insulin that causes an increase in glucagon
secretion by the alpha cells (Gosmanov et al., 2005), the lower level of circulating
plasma insulin as well as the rapid rate of decline in blood glucose levels following EX
may explain this late increase in plasma glucagon levels.
Regardless of the mechanism underlying the glycaemia-increasing effect of a 30-second
sprint, the faster decrease in blood glucose levels when sprinting is performed after a
bout of antecedent moderate-intensity exercise in non-diabetic individuals may have
important clinical implications for individuals with T1DM. However, since the rise in
plasma insulin plays a large role in the decline of blood glucose levels after intense
exercise in non-diabetic individuals (Purdon et al., 1993; Sigal et al., 1994), individuals
with T1DM may respond differently. Given the inability of these individuals to change
their circulating level of plasma insulin, blood glucose levels remain elevated after
intense exercise in individuals with T1DM (Mitchell et al., 1988; Purdon et al., 1993;
Sigal et al., 1994). Therefore, it is unclear to what extent our findings in non-diabetic
individuals may be relevant to individuals with T1DM. Nevertheless, the possibility
remains that although sprinting may benefit individuals with T1DM, even if performed
several hours after a bout of antecedent moderate-intensity exercise, these individuals
should be cautious because the efficacy of a sprint in reducing the risk of
hypoglycaemia later in recovery may be compromised. For this reason, the effect of
antecedent exercise on the glycaemia-increasing effect of sprinting needs to be tested in
80
individuals with T1DM before valid guidelines can be given to these individuals and to
ensure that any differences in the blood glucose response to sprinting observed in the
lab is of clinical significance and has real-life application. Moreover, it is important to
note that one limitation of our study is that it focused on young physically active non-
diabetic males, thus raising the possibility that our findings may not be generalized to
other populations and that sprinting may not be warranted for individuals with
cardiovascular or respiratory diseases. For instance, there is evidence for marked
gender-based differences in glucose counterregulation and in the amount of blunting
caused by antecedent exercise, with females showing greater resistance to the blunting
effect of antecedent exercise (Galassetti et al., 2001). For this reason, future research
should investigate the effect of antecedent exercise on the glycaemia-increasing effect
of sprinting in females with and without T1DM.
In summary, although a bout of antecedent moderate-intensity exercise does not affect
the peak increase in blood glucose levels achieved after a 30-second sprint, it does alter
the efficacy of the 30-second sprint later in recovery, causing blood glucose levels to
decline more rapidly. This faster rate of decline in blood glucose levels may result from
enhanced insulin sensitivity and/or a blunted growth hormone response to sprinting, as
all the other counterregulatory hormones responded similarly in both trials. These
findings raise the possibility that antecedent exercise may also impair the protective
effect of sprinting against hypoglycaemia in individuals with T1DM. This highlights the
need for further research in individuals with T1DM before sprinting can be safely
recommended as a means of reducing the risk of exercise-mediated hypoglycaemia.
2.6 ReferencesAmerican College of Sports Medicine. (1998). The recommended quantity and quality
of exercise for developing and maintaining cardiorespiratory and muscular fitness,
and flexibility in healthy adults. Medicine & Science in Sports & Exercise, 30(6),
975-991.
Bolli, G.B. (2003). Treatment and prevention of hypoglycaemia and its unawareness in
type 1 diabetes mellitus. Reviews in Endocrine and Metabolic Disorders, 4(4),
335-341.
81
Bussau, V.A., Ferreira, L.D., Jones, T.W., & Fournier, P.A. (2006). The 10-s maximal
sprint: A novel approach to counter an exercise-mediated fall in glycaemia in
individuals with type 1 diabetes. Diabetes Care, 29(3), 601-606.
Bussau, V.A., Ferreira, L.D., Jones, T.W., & Fournier, P.A. (2007). A 10-s sprint
performed prior to moderate-intensity exercise prevents early post-exercise fall in
glycaemia in individuals with type 1 diabetes. Diabetologia, 50, 1815-1818.
Chiarelli, F., Verotti, A., Catino, M., Sabatino, G., & Pinelli, L. (1999). Hypoglycaemia
in children with type 1 diabetes mellitus. Acta Paediatrica Supplement, 427, 31-
34.
Choi, K., & Chisholm, D.J. (1996). Exercise and insulin-dependent diabetes mellitus
(T1D): Benefits and pitfalls. Australian and New Zealand Journal of Medicine,
26(6), 827-833.
Colberg, S.R. (2000). Use of clinical practice recommendations for exercise by
individuals with type 1 diabetes. The Diabetes Educator, 26(2), 265-271.
Colberg, S.R., & Swain, D.P. (2000). Exercise and diabetes control: A winning
combination. The Physician and Sportsmedicine, 28(4), 63-81.
Cryer, P.E., Davis, S.N., & Shamoon, H. (2003). Hypoglycaemia in diabetes. Diabetes
Care, 26(6), 1902-1912.
Derave, W., Hansen, B.F., Lund, S., Kristiansen, S., & Richter, E.A. (2000). Muscle
glycogen content affects insulin-stimulated glucose transport and protein
kinase B activity. American Journal of Physiology – Endocrinology and
Metabolism, 279(5), E947-E955.
Dill, D.B., & Costill, D.L. (1974). Calculation of percentages in volumes of blood,
plasma, and red cells in dehydration. Journal of Applied Physiology, 37(2),
247-248.
Galassetti, P., Mann, S., Tate, D., Neill, R.A., Wasserman, D.H., & Davis, S.N. (2001).
Effect of morning exercise on counterregulatory responses to subsequent,
afternoon exercise. Journal of Applied Physiology, 91(1), 91-99.
Goldstein, R.E., Abumrad, N.N., Lacy, D.B., Wasserman, D.H., & Cherrington, A.D.
(1995). Effects of an acute increase in epinephrine and cortisol on carbohydrate
metabolism during insulin deficiency. Diabetes, 44, 672-681.
82
Gollnick, P.D., Pernow, B., Essen, B., Jansson, E., & Saltin, B. (1981). Availability of
glycogen and plasma ffa for substrate utilisation in leg muscle of man during
exercise. Clinical Physiology, 1, 27-42.
Gosmanov, N.R., Szoke, E., Israelian, Z., Smith, T., Cryer, P.E., Gerich, J.E., & Meyer,
C. (2005). Role of the decrement in intraislet insulin for the glucagon response to
hypoglycaemia in humans. Diabetes Care, 28, 1124-1131.
Guelfi, K.J., Jones, T.W., & Fournier, P.A. (2005). The decline in blood glucose levels
is less with intermittent high-intensity compared with moderate exercise in
individuals with type 1 diabetes. Diabetes Care, 28(6), 1289-1294.
Guelfi, K.J., Ratnam, N., Smythe, G.A., Jones, T.W., & Fournier, P.A. (2007). Effect of
intermittent high-intensity compared with continuous moderate exercise on
glucose production and utilization in individuals with type 1 diabetes. American
Journal of Physiology – Endocrinology and Metabolism, 292, E865-E870.
Hannestad, U., & Lundblad, A. (1997). Accurate and precise isotope dilution mass
spectrometry method for determining glucose in whole blood. Clinical Chemistry,
43(5), 794-800.
Harmer, A.R., Ruell, P.A., McKenna, M.J., Chisholm, D.J., Hunter, S.K., Thom, J.M.,
Morris, N.R., & Flack, J.R. (2006). Effects of sprint training on extrarenal
potassium regulation with intense exercise in Type 1 diabetes. Journal of Applied
Physiology, 100, 26-34.
Kjaer, M. (1992). Regulation of hormonal and metabolic responses during exercise in
humans. Exercise and Sport Sciences Reviews, 20, 161-184.
Kreisman, S.H., Ah Mew, N., Arsenault, M., Nessim, S.J., Halter, J.B., Vranic, M., &
Marliss, E.B. (2000). Epinephrine infusion during moderate intensity exercise
increases glucose production and uptake. American Journal of Physiology –
Endocrinology and Metabolism, 278, E949-E957.
Kreisman, S.H., Halter, J.B., Vranic, M., & Marliss, E.B. (2003). Combined infusion of
epinephrine and norepinephrine during moderate exercise reproduces the
glucoregulatory response of intense exercise. Diabetes, 52, 1347-1354.
Liu, D., Moberg, E., Kollind, M., Lins, P-E., Adamson, U., & Macdonald, I.A. (1992).
Arterial, arterialized venous, venous, and capillary blood glucose measurement in
83
normal man during hyperinsulinemic euglycaemia and hypoglycaemia.
Diabetologia, 35, 287-290.
Lumb, A.N., & Gallen, I.W. (2009). Insulin dose adjustment and exercise in type 1
diabetes: what do we tell the patient? British Journal of Diabetes & Vascular
Disease, 9, 273-277.
Macdonald, M.J. (1987). Postexercise late onset hypoglycaemia in insulin-dependent
diabetic patients. Diabetes Care, 10, 584-588.
Marliss, E.B., Kreisman, S.H., Manzon, A., Halter, J.B., Vranic, M., & Nessim, S.J.
(2000). Gender differences in glucoregulatory responses to intense exercise.
Journal of Applied Physiology, 88, 457-466.
Marliss, E.B., & Vranic, M. (2002). Intense exercise has unique effects on both insulin
release and its roles in glucoregulation. Diabetes, 51, S271-S283.
McMahon, S.K., Ferreira, L.D., Ratnam, N., Davey, R.J., Youngs, L.M., Davis, E.A.,
Fournier, P.A., & Jones, T.W. (2007). Glucose requirements to maintain
euglycaemia after moderate-intensity afternoon exercise in adolescents with type
1 diabetes are increased in a biphasic manner. Journal of Clinical Endocrinology
and Metabolism, 92, 963-968.
Mitchell, T.H., Abraham, G., Schiffrin, A., Leiter, L.A., & Marliss, E.B. (1988).
Hyperglycaemia after intense exercise in IDDM subjects during continuous
subcutaneous insulin infusion. Diabetes Care, 11(4), 311-317.
Møller, N., Jorgensen, J.O.L., Schmitz, O., Møller, J., Christiansen, J.S., Alberti,
K.G.M.M., & Orskov, H. (1990). Effects of a growth hormone pulse on total and
forearm substrate fluxes in humans. American Journal of Physiology.
Endocrinology and Metabolism. 258, E86-E91.
Møller, N., Schmitz, O., Porksen, N., Møller, J., & Jorgensen, J.O.L. (1992). Dose-
response studies on the metabolic effects of a growth hormone pulse in humans.
Metabolism, 41, 172-175.
Morgan, W.P. (1985). Affective beneficience of vigorous physical activity. Medicine
and Science in Sports and Exercise, 17(1), 94-100.
Moussa, E., Zouhal, H., Vincent, S., Proiux, J., Delamarche, P., & Gratas-Delamarche,
A. (2003). Effect of sprint duration (6s or 30s) on plasma glucose regulation in
84
untrained male subjects. Journal of Sports Medicine and Physical Fitness, 43,
546-553.
Purdon, C., Brousson, M., Nyveen., Miles, P.D.G., Halter, J.B., Vranic, M., and
Marliss, E.B. (1993). The roles of insulin and catecholamines in the
glucoregulatory response during intense exercise and early recovery in insulin-
dependent diabetic and control subjects. Journal of Clinical Endocrinology and
Metabolism, 76, 566-573.
Raja, M.K., Raymer, G.H., Moran, G.R., Marsh, G., & Thompson, R.T. (2006).
Changes in tissue water content measured with multiple-frequency bioimpedance
and metabolism measured with 31P-MRS during progressive forearm exercise.
Journal of Applied Physiology, 101, 1070-1075.
Riddell, M.C., & Perkins, B.A. (2006). Type 1 diabetes and vigorous exercise:
Applications of exercise physiology to patient management. Canadian Journal of
Diabetes, 30(416), 63-71.
Rizza, R.A., Cryer, P.E., & Gerich, J.E. (1979). Role of glucagon, catecholamines, and
growth hormone in human glucose counterregulation. Journal of Clinical
Investigations, 64, 62-71.
Sigal, R.J., Purdon, C., Fisher, S.J., Halter, J.B., Vranic, M., & Marliss, E.B. (1994).
Hyperinsulinemia prevents prolonged hyperglycaemia after intense exercise in
insulin-dependent diabetic subjects. Journal of Clinical Endocrinology and
Metabolism, 79(4), 1049-1057.
Sjøgaard, G., Adams, R.P., & Saltin, B. (1985). Water and ion shifts in skeletal muscle
of humans with intense dynamic knee extension. American Journal of Physiology:
Regulatory Integrative Comparative Physiology, 248(17), R190-R196.
Sjøgaard, G., & Saltin, B. (1982). Extra- and intracellular water spaces in muscles of
man at rest and with dynamic exercise. American Journal of Physiology:
Regulatory Integrative Comparative Physiology, 243(12), R271-R280.
Sonstroem, R.J., & Morgan, W.P. (1989). Exercise and self-esteem: Rationale and
model. Medicine and Science in Sports and Exercise, 21(3), 329-337.
Tuominen, J.A., Karonen. S.L., Melamies, L., Bolli, G., & Koivisto, V.A. (1995).
Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting
insulin analogue. Diabetologia, 38, 106-111.
85
Ward, D.S., Hamilton, M.T., & Watson, P.D. (1996). Measurement of tissue volume
during non-steady state high-intensity muscle contraction. American Journal of
Physiology: Regulatory Integrative Comparative Physiology, 271, R1682-
R1690.
Watson, P.D., Garner, R.P., & Ward, D.S. (1993). Water uptake in stimulated cat
skeletal muscle. American Journal of Physiology: Regulatory Integrative
Comparative Physiology, 264, R790-R796.
Wolfe, R.R., and Chinkes, D.L. (2005). Isotope tracers in metabolic research 2nd Ed.
John Wiley & Sons.
86
Appendices
87
Appendix A
Testing Information Sheet and Consent Forms
88
Testing Information Sheet
Effect of antecedent exercise on the glycaemia-increasing effect of a short sprint
Aim of the study Recently, our research team discovered that as little as 10 seconds of high intensity exercise can cause an increase in blood glucose levels in people with type 1 diabetes mellitus (T1DM), and thereby prevent or delay a low blood glucose event (hypoglycaemia). However, it is possible that prior exercise may reduce the protective effect of a short sprint. The goal of this study is to determine whether moderate intensity exercise will reduce the ability of a short sprint to increase blood glucose levels in non-diabetic individuals. Why are you being approached You are being invited to participate in this study because you are a healthy non-diabetic individual aged between 18 and 30 years. You also fulfil the following criteria: you are not on any medication that will interfere with the study findings and you do not suffer from a chronic muscle or joint injury or any other health problem that may affect your ability to perform exercise. The study in brief If you agree to take part in this study, you will be asked to visit the Diabetes Research Laboratory at Princess Margaret Hospital on 3 separate occasions – on your first visit, your height and weight will be measured and you will be asked to perform a maximal rate of oxygen consumption (VO2 max) test on an exercise bike to determine your levels of fitness. You will also be given an accelerometer and instructions on how and when to use it. This will monitor your physical activity level prior to the study days. No less than 1 week later, you will return to the lab for your first study day – either an exercise day, or a rest day. At least 1 week later you will return to the lab for your second study day and final visit. Your second study day will be an exercise day or a rest day depending on what you did on your first study day. You will be asked to complete both an exercise day and a rest day. It is important that before each study day you meet the following restrictions:
you must have avoided any physical activity (excluding light walking) in the previous 72 hours
you must not have consumed caffeine or alcohol in the previous 24 hours
Princess Margaret Hospital for Children Roberts Road Subiaco WA 6008 GPO Box D184 Perth WA 6840
Tel: (08) 9340 8222 Fax: (08) 9340 8111 www.cahs.health.wa.gov.au
89
The study begins at 8 am and ends at approximately 2 pm, on both testing days. On arrival at the Research Unit, you will be provided with breakfast before a registered nurse will place a cannula (drip) into a vein on the back of your hand for the sampling of blood, and a second cannula will be inserted into one of the veins of your other forearm for the infusion of tagged glucose that has a heavy hydrogen attached to it. It is important to note that heavy hydrogen (also called deuterium) is harmless and that it is already present in moderate amounts in your body (close to 1g). This will allow us to keep track of the glucose inside your body. Once the cannulas are in place, you will be required to perform 60 minutes of moderate intensity exercise (equivalent to a light jog) on an exercise bike, or simply rest. Then, approximately 3 hours later, you will be required to perform a 30-second sprint on the same exercise bike. Following the sprint, you will be asked to sit comfortably for another 2 hours before the study ends. As mentioned above, you will return to the lab no less than 1 week later to perform the other treatment, either exercise or rest, before performing the 30-second sprint once more. Blood will be sampled at regular time intervals throughout the study, with a total volume of around 200 ml removed. This is far less than the volume removed when donating blood. On several occasions, we will also ask you to wear a mask to measure your rate of oxygen consumption. When you are not sprinting you can entertain yourself by watching light-hearted videos, listening to music, doing some light reading or just chatting with the research staff. We discourage any activity which will raise your adrenaline levels. Important Things to Note: 1. Your personal details and test results will be treated confidentially at all times. 2. It is important to stress that at any stage during the study you will retain the right to
withdraw your consent and to stop your participation in the study generally or in any specific aspect of it without impacting on your relationship with Princess Margaret Hospital for Children or the University of Western Australia.
Should you have any further questions concerning the study, please contact Prof Paul Fournier (6488 1356). If you have any complaints regarding the conduct of this study, please contact the Executive Director, Medical Services, PMH on 9340 8222.
Princess Margaret Hospital for Children Roberts Road Subiaco WA 6008 GPO Box D184 Perth WA 6840
Tel: (08) 9340 8222 Fax: (08) 9340 8111 www.cahs.health.wa.gov.au
90
Consent Form
Effect of antecedent exercise on the glycaemia-increasing effect of a short sprint
I, the undersigned (print your name) _______________________________ do freely and voluntarily give consent to be a subject in a study aimed at assessing the effect of moderate intensity exercise on the blood glucose response to a 30-second sprint.
I declare that the purposes of this study have been fully explained to me. I realize that I will be required to undertake 60 minutes of moderate intensity exercise before performing a 30-second sprint, and I am also aware of other procedures (including the sampling of blood) that will take place during the study. I understand that blood sampling is necessary, and the risks associated with this are minor, and may include minimal discomfort and minimal pain and bruising at the site of sampling. Whilst I hereby indicate my willingness to act as a subject in this study, I retain the right to withdraw my consent at any time and to discontinue my participation in the study generally or in any specific aspect of it. I understand that my participation in this study does not prejudice any right to compensation, which I may have under statute or common law. I have read and understood the information sheet about testing and any questions I have asked have been answered to my satisfaction. Should you have any further questions concerning this project please contact: Prof Paul Fournier on 6488 1356. Finally I declare that any research obtained from the results of the test to be conducted can be published in scientific papers, provided that my name is not mentioned. ___________________________ _________________________ Signature of participant Date ________________________ _________________________ Signature of investigator Date
Princess Margaret Hospital for Children Roberts Road Subiaco WA 6008 GPO Box D184 Perth WA 6840
Tel: (08) 9340 8222 Fax: (08) 9340 8111 www.cahs.health.wa.gov.au
91
Appendix B
Human Ethics Approval Form
92
93
94
95
96
Appendix C
Meal Record Sheet
97
Instruction Sheet for Food Record Keeping
The purpose of filling out a food record sheet in this study is to ensure that you consume a similar diet on the day prior to each experimental trial. This is an important part of the study and needs to be done with care and accuracy. You don’t need to change your eating habits, but you need to match what you eat the day before the first trial to what you eat the day before the second trial.
What you need to do:
1. Record all food and drinks that you consume.
2. Measure your food by using cup measures or teaspoon/tablespoons.
3. Write the time of day that you consume food or drink.
Remember: You must not consume caffeine or alcohol on the day prior to each testing
session.
You must fast for 10 hours prior to coming into the laboratory (i.e. no food
or drink, except water from 10pm the prior evening).
You must consume the breakfast provided to you at 7:20am before coming
to the laboratory.
98
MEAL RECORD: DAY BEFORE FIRST VISIT What did you eat for breakfast? (And how much) TIME: Drinks: What did you eat for morning tea? (And how much) TIME: Drinks: What did you eat for lunch? (And how much) TIME: Drinks: What did you eat for afternoon tea? (And how much) TIME: Drinks: What did you eat for dinner? (And how much) TIME: Drinks: What did you eat for dessert? (And how much) TIME:
99
MEAL RECORD: DAY BEFORE SECOND VISIT
What did you eat for breakfast? (And how much) TIME: Drinks: What did you eat for morning tea? (And how much) TIME: Drinks: What did you eat for lunch? (And how much) TIME: Drinks: What did you eat for afternoon tea? (And how much) TIME: Drinks: What did you eat for dinner? (And how much) TIME: Drinks: What did you eat for dessert? (And how much) TIME: Drinks:
100
Appendix D
Data Collection Sheets
101
102
103